1
|
Latic N, Erben RG. Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System. Nutrients 2022; 14:nu14235186. [PMID: 36501215 PMCID: PMC9736617 DOI: 10.3390/nu14235186] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 11/29/2022] [Accepted: 12/01/2022] [Indexed: 12/12/2022] Open
Abstract
The seminal discoveries that parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) are major endocrine regulators of vitamin D metabolism led to a significant improvement in our understanding of the pivotal roles of peptide hormones and small proteohormones in the crosstalk between different organs, regulating vitamin D metabolism. The interaction of vitamin D, FGF23 and PTH in the kidney is essential for maintaining mineral homeostasis. The proteohormone FGF23 is mainly secreted from osteoblasts and osteoclasts in the bone. FGF23 acts on proximal renal tubules to decrease production of the active form of vitamin D (1,25(OH)2D) by downregulating transcription of 1α-hydroxylase (CYP27B1), and by activating transcription of the key enzyme responsible for vitamin D degradation, 24-hydroxylase (CYP24A1). Conversely, the peptide hormone PTH stimulates 1,25(OH)2D renal production by upregulating the expression of 1α-hydroxylase and downregulating that of 24-hydroxylase. The circulating concentration of 1,25(OH)2D is a positive regulator of FGF23 secretion in the bone, and a negative regulator of PTH secretion from the parathyroid gland, forming feedback loops between kidney and bone, and between kidney and parathyroid gland, respectively. In recent years, it has become clear that vitamin D signaling has important functions beyond mineral metabolism. Observation of seasonal variations in blood pressure and the subsequent identification of vitamin D receptor (VDR) and 1α-hydroxylase in non-renal tissues such as cardiomyocytes, endothelial and smooth muscle cells, suggested that vitamin D may play a role in maintaining cardiovascular health. Indeed, observational studies in humans have found an association between vitamin D deficiency and hypertension, left ventricular hypertrophy and heart failure, and experimental studies provided strong evidence for a role of vitamin D signaling in the regulation of cardiovascular function. One of the proposed mechanisms of action of vitamin D is that it functions as a negative regulator of the renin-angiotensin-aldosterone system (RAAS). This finding established a novel link between vitamin D and RAAS that was unexplored until then. During recent years, major progress has been made towards a more complete understanding of the mechanisms by which FGF23, PTH, and RAAS regulate vitamin D metabolism, especially at the genomic level. However, there are still major gaps in our knowledge that need to be filled by future research. The purpose of this review is to highlight our current understanding of the molecular mechanisms underlying the interaction between vitamin D, FGF23, PTH, and RAAS, and to discuss the role of these mechanisms in physiology and pathophysiology.
Collapse
|
2
|
Buck A, Prade VM, Kunzke T, Erben RG, Walch A. Spatial metabolomics reveals upregulation of several pyrophosphate-producing pathways in cortical bone of Hyp mice. JCI Insight 2022; 7:162138. [DOI: 10.1172/jci.insight.162138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 08/31/2022] [Indexed: 11/17/2022] Open
|
3
|
Latic N, Zupcic A, Frauenstein D, Erben RG. Activation of RAAS Signaling Contributes to Hypertension in Aged Hyp Mice. Biomedicines 2022; 10:biomedicines10071691. [PMID: 35884995 PMCID: PMC9313116 DOI: 10.3390/biomedicines10071691] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 07/05/2022] [Accepted: 07/09/2022] [Indexed: 12/12/2022] Open
Abstract
High circulating levels of fibroblast growth factor-23 (FGF23) are associated with left ventricular hypertrophy as well as increased morbidity and mortality in patients suffering from chronic kidney disease. However, the mechanisms underlying this association are controversial. Here, we aimed to further characterize the cardiovascular sequelae of long term endogenous FGF23 hypersecretion using 14-month-old male Hyp mice as a model of FGF23 excess. Hyp mice were characterized by a ~10-fold increase in circulating intact FGF23, hypophosphatemia, increased serum aldosterone, but normal kidney function, relative to wildtype (WT) controls. Cardiovascular phenotyping did not reveal any evidence of left ventricular hypertrophy or functional impairment in 14-month-old Hyp mice. Fractional shortening, ejection fraction, molecular markers of hypertrophy (Anp, Bnp), and intracardiac markers of contractility and diastolic function were all unchanged in these animals. However, intraarterial catheterization revealed an increase in systolic, diastolic, and mean arterial pressure of ~12 mm Hg in aged Hyp mice relative to WT controls. Hypertension in Hyp mice was associated with increased peripheral vascular resistance. To test the hypothesis that a stimulation of the renin–angiotensin–aldosterone system (RAAS) contributes to hypertension in aged Hyp mice, we administered the angiotensin receptor blocker losartan (30 mg/kg twice daily) or the mineralocorticoid receptor antagonist canrenone (30 mg/kg once daily) to aged Hyp and WT mice over 5 days. Both drugs had minor effects on blood pressure in WT mice, but reduced blood pressure and peripheral vascular resistance in Hyp mice, suggesting that a stimulation of the RAAS contributes to hypertension in aged Hyp mice.
Collapse
|
4
|
Mosti MP, Stafne SN, Sujan MAJ, Redalen KR, Marthinsen ABL, Skallerud BH, Auestad M, Nogueira LP, Reseland JE, Erben RG, Syversen U, Stunes AK. Strength training reduces radiation-induced bone deterioration and maintains lean mass in a rat model. Bone Rep 2022. [DOI: 10.1016/j.bonr.2022.101369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
5
|
Abstract
Apart from its phosphaturic action, the bone-derived hormone fibroblast growth factor-23 (FGF23) is also an essential regulator of vitamin D metabolism. The main target organ of FGF23 is the kidney, where FGF23 suppresses transcription of the key enzyme in vitamin D hormone (1,25(OH)2D) activation, 1α-hydroxylase, and activates transcription of the key enzyme responsible for vitamin D degradation, 24-hydroxylase, in proximal renal tubules. The circulating concentration of 1,25(OH)2D is a positive regulator of FGF23 secretion in bone, forming a feedback loop between kidney and bone. The importance of FGF23 as regulator of vitamin D metabolism is underscored by the fact that in the absence of FGF23 signaling, the tight control of renal 1α-hydroxylase fails, resulting in overproduction of 1,25(OH)2D in mice and men. During recent years, big strides have been made toward a more complete understanding of the mechanisms underlying the FGF23-mediated regulation of vitamin D metabolism, especially at the genomic level. However, there are still major gaps in our knowledge that need to be filled by future research. Importantly, the intracellular signaling cascades downstream of FGF receptors regulating transcription of 1α-hydroxylase and 24-hydroxylase in proximal renal tubules still remain unresolved. The purpose of this review is to highlight our current understanding of the molecular mechanisms underlying the regulation of vitamin D metabolism by FGF23, and to discuss the role of these mechanisms in physiology and pathophysiology. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Nejla Latic
- Department of Biomedical Sciences University of Veterinary Medicine Vienna Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences University of Veterinary Medicine Vienna Austria
| |
Collapse
|
6
|
Radloff J, Latic N, Pfeiffenberger U, Schüler C, Tangermann S, Kenner L, Erben RG. A phosphate and calcium-enriched diet promotes progression of 5/6-nephrectomy-induced chronic kidney disease in C57BL/6 mice. Sci Rep 2021; 11:14868. [PMID: 34290280 PMCID: PMC8295299 DOI: 10.1038/s41598-021-94264-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 07/06/2021] [Indexed: 02/06/2023] Open
Abstract
C57BL/6 mice are known to be rather resistant to the induction of experimental chronic kidney disease (CKD) by 5/6-nephrectomy (5/6-Nx). Here, we sought to characterize the development of CKD and its cardiac and skeletal sequelae during the first three months after 5/6-Nx in C57BL/6 mice fed a calcium- and phosphate enriched diet (CPD) with a balanced calcium/phosphate ratio. 5/6-NX mice on CPD showed increased renal fibrosis and a more pronounced decrease in glomerular filtration rate when compared to 5/6-Nx mice on normal diet (ND). Interestingly, despite comparable levels of serum calcium, phosphate, and parathyroid hormone (PTH), circulating intact fibroblast growth factor-23 (FGF23) was 5 times higher in 5/6-Nx mice on CPD, relative to 5/6-Nx mice on ND. A time course experiment revealed that 5/6-Nx mice on CPD developed progressive renal functional decline, renal fibrosis, cortical bone loss, impaired bone mineralization as well as hypertension, but not left ventricular hypertrophy. Collectively, our data show that the resistance of C57BL/6 mice to 5/6-Nx can be partially overcome by feeding the CPD, and that the CPD induces a profound, PTH-independent increase in FGF23 in 5/6-Nx mice, making it an interesting tool to assess the pathophysiological significance of FGF23 in CKD.
Collapse
Affiliation(s)
- J Radloff
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - N Latic
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - U Pfeiffenberger
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - C Schüler
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - S Tangermann
- Department of Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
| | - L Kenner
- Department of Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
| | - R G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria.
| |
Collapse
|
7
|
Bayer J, Vaghela R, Drechsler S, Osuchowski MF, Erben RG, Andrukhova O. The bone is the major source of high circulating intact fibroblast growth factor-23 in acute murine polymicrobial sepsis induced by cecum ligation puncture. PLoS One 2021; 16:e0251317. [PMID: 33989306 PMCID: PMC8121358 DOI: 10.1371/journal.pone.0251317] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 04/23/2021] [Indexed: 12/20/2022] Open
Abstract
Fibroblast growth factor-23 (FGF23), a bone-produced hormone, plays a critical role in mineral homeostasis. Human diseases associated with excessive intact circulating FGF23 (iFGF23) result in hypophosphatemia and low vitamin D hormone in patients with normal kidney function. In addition, there is accumulating evidence linking FGF23 with inflammation. Based on these studies and the frequent observation of hypophosphatemia among septic patients, we sought to elucidate further the relationship between FGF23 and mineral homeostasis in a clinically relevant murine polymicrobial sepsis model. Medium-severity sepsis was induced by cecum ligation puncture (CLP) in adult CD-1 mice of both sexes. Healthy CD-1 mice (without CLP) were used as controls. Forty-eight hours post-CLP, spontaneous urine was collected, and serum, organs and bones were sampled at necropsy. Serum iFGF23 increased ~20-fold in CLP compared to control mice. FGF23 protein concentration was increased in the bones, but not in spleen or liver of CLP mice. Despite the ~20-fold iFGF23 increase, we did not observe any significant changes in mineral homeostasis or parathyroid hormone levels in the blood of CLP animals. Urinary excretion of phosphate, calcium, and sodium remained unchanged in male CLP mice, whereas female CLP mice exhibited lower urinary calcium excretion, relative to healthy controls. In line with renal FGF23 resistance, expression of phosphate-, calcium- and sodium-transporting proteins did not show consistent changes in the kidneys of male and female CLP mice. Renal expression of the co-receptor αKlotho was downregulated in female, but not in male CLP mice. In conclusion, our data demonstrate that the dramatic, sex-independent rise in serum iFGF23 post-CLP was mainly caused by an upregulation of FGF23 secretion in the bone. Surprisingly, the upsurge in circulating iFGF23 did not alter humoral mineral homeostasis in the acutely septic mice. Hence, the biological function of elevated FGF23 in sepsis remains unclear and warrants further studies.
Collapse
Affiliation(s)
- Jessica Bayer
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Ravikumar Vaghela
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Susanne Drechsler
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria
| | - Marcin F. Osuchowski
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria
| | - Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
- * E-mail:
| | - Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
8
|
Radloff J, Pagitz M, Andrukhova O, Oberbauer R, Burgener IA, Erben RG. Aldosterone Is Positively Associated With Circulating FGF23 Levels in Chronic Kidney Disease Across Four Species, and May Drive FGF23 Secretion Directly. Front Physiol 2021; 12:649921. [PMID: 33995120 PMCID: PMC8117232 DOI: 10.3389/fphys.2021.649921] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 04/06/2021] [Indexed: 11/13/2022] Open
Abstract
Background Chronic kidney disease (CKD) is accompanied by increases in circulating fibroblast growth factor 23 (FGF23) and aldosterone levels. Here, we tested the hypothesis that aldosterone may be one of the driving forces behind increased FGF23 secretion in CKD. Methods Using data from a prospective study in humans, a retrospective study in dogs and cats, and an experimental study in 5/6-nephrectomized mice, we analyzed the relationship between circulating FGF23 and serum aldosterone levels in CKD across four species. To assess the effects of acute inhibition of aldosterone signaling on circulating FGF23, we acutely treated mice with established CKD with the mineralocorticoid receptor blocker canrenone (50 mg/kg iv/sc), and measured intact FGF23 before and 24 h as well as 72 h after start of administration of the drug. Results We found a tight positive association between circulating intact FGF23 and serum aldosterone in human, canine, and feline CKD patients, as well as in experimental murine CKD (humans: r S = 0.57, p = 0.0368; dogs: r S = 0.66, p = 0.0019; cats: r S = 0.75, p = 0.0003; mice: r S = 0.49, p = 0.0004). Injection of canrenone in mice with established CKD did not lead to changes in FGF23 levels within 24 h, but reduced FGF23 in all mice at 72 h. Conclusion Aldosterone may drive enhanced FGF23 secretion in CKD, possibly explaining the tight positive association between circulating intact FGF23 and aldosterone in human, canine, and feline CKD patients as well as in experimental CKD models.
Collapse
Affiliation(s)
- Judith Radloff
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Maximilian Pagitz
- Division of Small Animal Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Rainer Oberbauer
- Department of Nephrology, Medical University of Vienna, Vienna, Austria
| | - Iwan A Burgener
- Division of Small Animal Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
9
|
Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R, Beitzke D, Wielandner A, Erben RG, Oberbauer R. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res 2021; 128:1616-1625. [PMID: 33825489 DOI: 10.1161/circresaha.120.318556] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Katharina Dörr
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.)
| | - Michael Kammer
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.).,Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Section for Clinical Biometrics (M.K.D.-I.)
| | - Roman Reindl-Schwaighofer
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.)
| | | | | | | | - Dietrich Beitzke
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.).,Biomedical Imaging and Image-guided Therapy, and Division of Cardiovascular and Interventional Radiology (D.B., A.W.)
| | - Alice Wielandner
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.).,Biomedical Imaging and Image-guided Therapy, and Division of Cardiovascular and Interventional Radiology (D.B., A.W.)
| | | | - Rainer Oberbauer
- Department of Nephrology and Dialysis, Medical University of Vienna (K.D., M.K.D.I., R.R.-S., R.O., D.B., A.W.)
| |
Collapse
|
10
|
Misof BM, Blouin S, Hofstaetter JG, Roschger P, Zwerina J, Erben RG. No Role of Osteocytic Osteolysis in the Development and Recovery of the Bone Phenotype Induced by Severe Secondary Hyperparathyroidism in Vitamin D Receptor Deficient Mice. Int J Mol Sci 2020; 21:E7989. [PMID: 33121142 PMCID: PMC7662929 DOI: 10.3390/ijms21217989] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 10/16/2020] [Accepted: 10/22/2020] [Indexed: 12/13/2022] Open
Abstract
Osteocytic osteolysis/perilacunar remodeling is thought to contribute to the maintenance of mineral homeostasis. Here, we utilized a reversible, adult-onset model of secondary hyperparathyroidism to study femoral bone mineralization density distribution (BMDD) and osteocyte lacunae sections (OLS) based on quantitative backscattered electron imaging. Male mice with a non-functioning vitamin D receptor (VDRΔ/Δ) or wild-type mice were exposed to a rescue diet (RD) (baseline) and subsequently to a low calcium challenge diet (CD). Thereafter, VDRΔ/Δ mice received either the CD, a normal diet (ND), or the RD. At baseline, BMDD and OLS characteristics were similar in VDRΔ/Δ and wild-type mice. The CD induced large cortical pores, osteomalacia, and a reduced epiphyseal average degree of mineralization in the VDRΔ/Δ mice relative to the baseline (-9.5%, p < 0.05 after two months and -10.3%, p < 0.01 after five months of the CD). Switching VDRΔ/Δ mice on the CD back to the RD fully restored BMDD to baseline values. However, OLS remained unchanged in all groups of mice, independent of diet. We conclude that adult VDRΔ/Δ animals on an RD lack any skeletal abnormalities, suggesting that VDR signaling is dispensable for normal bone mineralization as long as mineral homeostasis is normal. Our findings also indicate that VDRΔ/Δ mice attempt to correct a calcium challenge by enhanced osteoclastic resorption rather than by osteocytic osteolysis.
Collapse
Affiliation(s)
- Barbara M. Misof
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Deptartment, Hanusch Hospital, 11140 Vienna, Austria; (S.B.); (J.G.H.); (P.R.); (J.Z.)
| | - Stéphane Blouin
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Deptartment, Hanusch Hospital, 11140 Vienna, Austria; (S.B.); (J.G.H.); (P.R.); (J.Z.)
| | - Jochen G. Hofstaetter
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Deptartment, Hanusch Hospital, 11140 Vienna, Austria; (S.B.); (J.G.H.); (P.R.); (J.Z.)
- Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna Speising, 1130 Vienna, Austria
| | - Paul Roschger
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Deptartment, Hanusch Hospital, 11140 Vienna, Austria; (S.B.); (J.G.H.); (P.R.); (J.Z.)
| | - Jochen Zwerina
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Deptartment, Hanusch Hospital, 11140 Vienna, Austria; (S.B.); (J.G.H.); (P.R.); (J.Z.)
| | - Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, 1210 Vienna, Austria;
| |
Collapse
|
11
|
Krylatov AV, Tsibulnikov SY, Mukhomedzyanov AV, Boshchenko AA, Goldberg VE, Jaggi AS, Erben RG, Maslov LN. The Role of Natriuretic Peptides in the Regulation of Cardiac Tolerance to Ischemia/Reperfusion and Postinfarction Heart Remodeling. J Cardiovasc Pharmacol Ther 2020; 26:131-148. [PMID: 32840121 DOI: 10.1177/1074248420952243] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
In the past 10 years, mortality from acute myocardial infarction has not decreased despite the widespread introduction of percutaneous coronary intervention. The reason for this situation is the absence in clinical practice of drugs capable of preventing reperfusion injury of the heart with high efficiency. In this regard, noteworthy natriuretic peptides (NPs) which have the infarct-limiting effect, prevent reperfusion cardiac injury, prevent adverse post-infarction remodeling of the heart. Atrial natriuretic peptide does not have the infarct-reducing effect in rats with alloxan-induced diabetes mellitus. NPs have the anti-apoptotic and anti-inflammatory effects. There is indirect evidence that NPs inhibit pyroptosis and autophagy. Published data indicate that NPs inhibit reactive oxygen species production in cardiomyocytes, aorta, heart, kidney and the endothelial cells. NPs can suppress aldosterone, angiotensin II, endothelin-1 synthesize and secretion. NPs inhibit the effects aldosterone, angiotensin II on the post-receptor level through intracellular signaling events. NPs activate guanylyl cyclase, protein kinase G and protein kinase A, and reduce phosphodiesterase 3 activity. NO-synthase and soluble guanylyl cyclase are involved in the cardioprotective effect of NPs. The cardioprotective effect of natriuretic peptides is mediated via activation of kinases (AMPK, PKC, PI3 K, ERK1/2, p70s6 k, Akt) and inhibition of glycogen synthase kinase 3β. The cardioprotective effect of NPs is mediated via sarcolemmal KATP channel and mitochondrial KATP channel opening. The cardioprotective effect of brain natriuretic peptide is mediated via MPT pore closing. The anti-fibrotic effect of NPs may be mediated through inhibition TGF-β1 expression. Natriuretic peptides can inhibit NF-κB activity and activate GATA. Hemeoxygenase-1 and peroxisome proliferator-activated receptor γ may be involved in the infarct-reducing effect of NPs. NPs exhibit the infarct-limiting effect in patients with acute myocardial infarction. NPs prevent post-infarction remodeling of the heart. To finally resolve the question of the feasibility of using NPs in AMI, a multicenter, randomized, blind, placebo-controlled study is needed to assess the effect of NPs on the mortality of patients after AMI.
Collapse
Affiliation(s)
- Andrey V Krylatov
- Cardiology Research Institute, 164253Tomsk National Research Medical Center of the RAS, Tomsk, Russia
| | - Sergey Y Tsibulnikov
- Cardiology Research Institute, 164253Tomsk National Research Medical Center of the RAS, Tomsk, Russia
| | | | - Alla A Boshchenko
- Cardiology Research Institute, 164253Tomsk National Research Medical Center of the RAS, Tomsk, Russia
| | - Victor E Goldberg
- Cancer Research Institute, 164253Tomsk National Research Medical Center of the RAS, Tomsk, Russia
| | - Amteshwar S Jaggi
- 429174Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
| | - Reinhold G Erben
- Department of Biomedical Research, Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Leonid N Maslov
- Cardiology Research Institute, 164253Tomsk National Research Medical Center of the RAS, Tomsk, Russia
| |
Collapse
|
12
|
Pál É, Hricisák L, Lékai Á, Nagy D, Fülöp Á, Erben RG, Várbíró S, Sándor P, Benyó Z. Ablation of Vitamin D Signaling Compromises Cerebrovascular Adaptation to Carotid Artery Occlusion in Mice. Cells 2020; 9:cells9061457. [PMID: 32545499 PMCID: PMC7349396 DOI: 10.3390/cells9061457] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 06/09/2020] [Accepted: 06/10/2020] [Indexed: 12/14/2022] Open
Abstract
Vitamin D insufficiency has been associated with increased incidence and severity of cerebrovascular disorders. We analyzed the impact of impaired vitamin D signaling on the anatomical and functional aspects of cerebrovascular adaptation to unilateral carotid artery occlusion (CAO), a common consequence of atherosclerosis and cause of ischemic stroke. Cerebrocortical blood flow (CoBF) showed a significantly increased drop and delayed recovery after CAO in mice carrying a functionally inactive vitamin D receptor (VDR) with the most sustained perfusion deficit in the temporal cortex. To identify the cause(s) for this altered adaptation, the extent of compensatory blood flow increase in the contralateral carotid artery and the morphology of pial collaterals between the anterior and middle cerebral arteries were determined. Whereas VDR deficiency had no significant influence on the contralateral carotid arterial blood flow increase, it was associated with decreased number and increased tortuosity of pial anastomoses resulting in unfavorable changes of the intracranial collateral circulation. These results indicate that VDR deficiency compromises the cerebrovascular adaptation to CAO with the most sustained consequences in the temporal cortex. The dysregulation can be attributed to the altered development and function of pial collateral circulation whereas extracranial vessels may not be impaired.
Collapse
Affiliation(s)
- Éva Pál
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
- Correspondence: (É.P.); (Z.B.); Tel.: +36-1-210-0306 (É.P.); +36-1-210-0306 (Z.B.)
| | - László Hricisák
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
| | - Ágnes Lékai
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
| | - Dorina Nagy
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
| | - Ágnes Fülöp
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
| | - Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, 1210 Vienna, Austria;
| | - Szabolcs Várbíró
- Department of Obstetrics and Gynecology, Semmelweis University, 1082 Budapest, Hungary;
| | - Péter Sándor
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
| | - Zoltán Benyó
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary; (L.H.); (Á.L.); (D.N.); (Á.F.); (P.S.)
- Correspondence: (É.P.); (Z.B.); Tel.: +36-1-210-0306 (É.P.); +36-1-210-0306 (Z.B.)
| |
Collapse
|
13
|
Stunes AK, Erben RG, Schüler C, Eriksen EF, Tice M, Vashishth D, Syversen U, Mosti MP. Skeletal effects of plyometric exercise and metformin in ovariectomized rats. Bone 2020; 132:115193. [PMID: 31857252 DOI: 10.1016/j.bone.2019.115193] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 12/13/2019] [Accepted: 12/16/2019] [Indexed: 01/14/2023]
Abstract
Estrogen deficiency causes bone loss and skeletal muscle dysfunction, and attenuates the musculoskeletal effects of exercise. The anti-diabetic drug metformin has been suggested to promote beneficial skeletal effects. To explore whether metformin can improve musculoskeletal training response during estrogen deficiency, we investigated the skeletal effects of plyometric exercise and metformin, in an ovarectomized (OVX) rat model of osteoporosis. Female Sprague Dawley rats, 12 weeks of age, rats were allocated to a sham-operated group (Sham), and four OVX groups; metformin (OVX-Met), exercise (OVX-Ex), combined metformin and exercise (OVX-MetEx) and a control group (OVX-Ctr), n = 12/group. Dual X-ray absorptiometry, micro computed tomography, fracture toughness testing, histomorphometry and plasma analyses were performed to explore skeletal effects. All intervention groups exhibited a higher gain in femoral bone mineral density (BMD) than OVX-Ctr (p < .01). The combined intervention also resulted in a higher gain in femoral and spine BMD compared to OVX-Met (p < .01). Both exercise groups displayed improved microarchitecture, including both cortical and trabecular parameters (p < .05). This was most evident in the OVX-MetEx group where several indices were at sham level or superior to OVX-Ctr (p < .05). The OVX-MetEx group also exhibited an enhanced toughening effect compared to the other OVX groups (p < .05). The beneficial skeletal effects seemed to be mediated by inhibition of bone resorption and stimulation of bone formation. The training response (i.e. jumping height) was also greater in the metformin treated rats compared to OVX-Ex (p < .01), indicating a performance-enhancing effect of metformin. Both exercise groups displayed higher lean mass than OVX-Ctr (p < .05). In conclusion, the combination of plyometric exercise and metformin improved trabecular microarchitecture and bone material properties relative to OVX controls. However, no additive effect of the combined intervention was observed compared to exercise alone.
Collapse
Affiliation(s)
- A K Stunes
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; St. Olavs University Hospital, Trondheim, Norway
| | - R G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - C Schüler
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - E F Eriksen
- Department of Endocrinology, Oslo University Hospital, Oslo, Norway
| | - M Tice
- Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA
| | - D Vashishth
- Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA
| | - U Syversen
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Endocrinology, St Olavs University Hospital HF, Trondheim, Norway
| | - M P Mosti
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; St. Olavs University Hospital, Trondheim, Norway.
| |
Collapse
|
14
|
Moschinger M, Hilse KE, Rupprecht A, Zeitz U, Erben RG, Rülicke T, Pohl EE. Age-related sex differences in the expression of important disease-linked mitochondrial proteins in mice. Biol Sex Differ 2019; 10:56. [PMID: 31806023 PMCID: PMC6896328 DOI: 10.1186/s13293-019-0267-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 10/17/2019] [Indexed: 11/10/2022] Open
Abstract
The prevalence and progression of many illnesses, such as neurodegenerative and cardiovascular diseases, obesity, and cancer, vary between women and men, often in an age-dependent manner. A joint hallmark of these diseases is some type of mitochondrial dysfunction. While several mitochondrial proteins are known to be regulated by sex hormones, the levels of those proteins have not been systematically analyzed with regard to sex and age, and studies that consider sex and/or age differences in the protein expression are very rare. In this study, we compared the expression patterns of physiologically important mitochondrial proteins in female and male C57BL/6N mice of age cohorts frequently used in experiments. We found that sex-related differences in the expression of uncoupling proteins 1 and 3 (UCP1 and UCP3) occur in an age-dependent manner. The sex-specific expression of UCP1 and UCP3 in brown adipose tissue (BAT) was inversely correlated with differences in body weight. Expression of UCP4 in the brain, Complex I in the spleen, and Complex II in the brain and BAT was least affected by the sex of the mouse. We further demonstrated that there are serious limitations in using VDAC1 and actin as markers in western blot analyses, due to their sex- and age-specific fluctuations. Our results confirm that sex and age are important parameters and should be taken into account by researchers who examine the mechanistic aspects of diseases. HIGHLIGHTS: I.The levels of UCP1 and UCP3 protein expression differ between females and males in an age-dependent manner.II.Pre-pubertal expression of almost all proteins tested in this study does not depend on the sex of the mouse.III.Expression of VDAC1 and actin, which are often used as loading control proteins in western blot analysis, is tissue-specifically influenced by sex and age.
Collapse
Affiliation(s)
- Michael Moschinger
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Karolina E Hilse
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Anne Rupprecht
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.,Institute of Pharmacology and Toxicology, Rostock University Medical Center, Rostock, Germany
| | - Ute Zeitz
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Thomas Rülicke
- Institute of Laboratory Animal Science, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Elena E Pohl
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.
| |
Collapse
|
15
|
Marek A, Schüler C, Satué M, Haigl B, Erben RG. A Laser Capture Microdissection Protocol That Yields High Quality RNA from Fresh-frozen Mouse Bones. J Vis Exp 2019. [PMID: 31566615 DOI: 10.3791/60197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
RNA yield and integrity are decisive for RNA analysis. However, it is often technically challenging to maintain RNA integrity throughout the entire laser capture microdissection (LCM) procedure. Since LCM studies work with low amounts of material, concerns about limited RNA yields are also important. Therefore, an LCM protocol was developed to obtain sufficient quantity of high-quality RNA for gene expression analysis in bone cells. The effect of staining protocol, thickness of cryosections, microdissected tissue quantity, RNA extraction kit, and LCM system used on RNA yield and integrity obtained from microdissected bone cells was evaluated. Eight-µm-thick frozen bone sections were made using an adhesive film and stained using a rapid protocol for a commercial LCM stain. The sample was sandwiched between a polyethylene terephthalate (PET) membrane and the adhesive film. An LCM system that uses gravity for sample collection and a column-based RNA extraction method were used to obtain high quality RNAs of sufficient yield. The current study focusses on mouse femur sections. However, the LCM protocol reported here can be used to study in situ gene expression in cells of any hard tissue in both physiological conditions and disease processes.
Collapse
Affiliation(s)
- Ana Marek
- Department of Biomedical Research, University of Veterinary Medicine Vienna
| | - Christiane Schüler
- Department of Biomedical Research, University of Veterinary Medicine Vienna
| | - María Satué
- Department of Biomedical Research, University of Veterinary Medicine Vienna
| | - Barbara Haigl
- Department of Biomedical Research, University of Veterinary Medicine Vienna
| | - Reinhold G Erben
- Department of Biomedical Research, University of Veterinary Medicine Vienna;
| |
Collapse
|
16
|
Hofstaetter JG, Misof BM, Jones DC, Zoehrer R, Blouin S, Schueler C, Paschalis EP, Erben RG, Weinkamer R, Klaushofer K, Roschger P. Biomechanical and Bone Material Properties of Schnurri-3 Null Mice. JBMR Plus 2019; 3:e10226. [PMID: 31768487 PMCID: PMC6874182 DOI: 10.1002/jbm4.10226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 07/01/2019] [Accepted: 07/04/2019] [Indexed: 12/31/2022] Open
Abstract
Schnurri‐3 (Shn3) is an essential regulator of postnatal skeletal remodeling. Shn3‐deficient mice (Shn3–/–) have high bone mass; however, their bone mechanical and material properties have not been investigated to date. We performed three‐point bending of femora, compression tests of L3 vertebrae. We also measured intrinsic material properties, including bone mineralization density distribution (BMDD) and osteocyte lacunae section (OLS) characteristics by quantitative backscatter electron imaging, as well as collagen cross‐linking by Fourier transform infrared microspectroscopy of femora from Shn3–/– and WT mice at different ages (6 weeks, 4 months, and 18 months). Moreover, computer modeling was performed for the interpretation of the BMDD outcomes. Femora and L3 vertebrae from Shn3–/– aged 6 weeks revealed increased ultimate force (2.2‐ and 3.2‐fold, p < .01, respectively). Mineralized bone volume at the distal femoral metaphysis was about twofold (at 6 weeks) to eightfold (at 4 and 18 months of age) in Shn3–/– (p < .001). Compared with WT, the average degree of trabecular bone mineralization was similar at 6 weeks, but increased at 4 and 18 months of age (+12.6% and +7.7%, p < .01, respectively) in Shn3–/–. The analysis of OLS characteristics revealed a higher OLS area for Shn3–/– versus WT at all ages (+16%, +23%, +21%, respectively, p < .01). The collagen cross‐link ratio was similar between groups. We conclude that femora and vertebrae from Shn3–/– had higher ultimate force in mechanical testing. Computer modeling demonstrated that in cases of highly increased bone volume, the average degree of bone matrix mineralization can be higher than in WT bone, which was actually measured in the older Shn3–/– groups. The area of 2D osteocyte lacunae sections was also increased in Shn3‐deficiency, which could only partly be explained by larger remnant areas of primary cortical bone. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Jochen G Hofstaetter
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria.,Orthopaedic Hospital Vienna Speising Vienna Austria
| | - Barbara M Misof
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| | - Dallas C Jones
- Department of Immunology and Infectious Diseases Harvard School of Public Health Boston MA USA
| | - Ruth Zoehrer
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| | - Stéphane Blouin
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| | - Christiane Schueler
- Department of Biomedical Sciences University of Veterinary Medicine Vienna Austria
| | - Eleftherios P Paschalis
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences University of Veterinary Medicine Vienna Austria
| | - Richard Weinkamer
- Department of Biomaterials Max Planck Institute of Colloids and Interfaces Potsdam Germany
| | - Klaus Klaushofer
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| | - Paul Roschger
- 1st Medical Department Hanusch Hospital Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling Vienna Austria
| |
Collapse
|
17
|
Erben RG. Editorial: Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease. Front Endocrinol (Lausanne) 2019; 10:2. [PMID: 30719022 PMCID: PMC6348246 DOI: 10.3389/fendo.2019.00002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 01/03/2019] [Indexed: 11/13/2022] Open
Affiliation(s)
- Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
18
|
Abstract
Bone histomorphometry remains an important tool with which to study the pathophysiology of bone disease and the cellular mechanism by which treatments work. Here we review the methods for embedding, sectioning, staining, and analysis of bone sections in rodents.
Collapse
Affiliation(s)
- Reinhold G Erben
- Department of Biomedical Sciences, Institute of Physiology, Pathophysiology, and Biophysics, University of Veterinary Medicine, Vienna, Austria.
| | - Martin Glösmann
- VetCore Facility for Research, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
19
|
Ford K, Latic N, Slavic S, Zeitz U, Dolezal M, Andrukhov O, Erben RG, Andrukhova O. Lack of vitamin D signalling per se does not aggravate cardiac functional impairment induced by myocardial infarction in mice. PLoS One 2018; 13:e0204803. [PMID: 30273386 PMCID: PMC6166969 DOI: 10.1371/journal.pone.0204803] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Accepted: 08/20/2018] [Indexed: 12/18/2022] Open
Abstract
Epidemiological studies have linked vitamin D deficiency to an increased incidence of myocardial infarction and support a role for vitamin D signalling in the pathophysiology of myocardial infarction. Vitamin D deficiency results in the development of secondary hyperparathyroidism, however, the role of secondary hyperparathyroidism in the pathophysiology of myocardial infarction is not known. Here, we aimed to explore further the secondary hyperparathyroidism independent role of vitamin D signalling in the pathophysiology of myocardial infarction by inducing experimental myocardial infarction in 3-month-old, male, wild-type mice and in mice lacking a functioning vitamin D receptor. In order to prevent secondary hyperparathyroidism in vitamin D receptor mutant mice, all mice were maintained on a rescue diet enriched with calcium, phosphorus, and lactose. Surprisingly, survival rate, cardiac function as measured by echocardiography and intra-cardiac catheterisation and cardiomyocyte size were indistinguishable between normocalcaemic vitamin D receptor mutant mice and wild-type controls, 2 and 8 weeks post-myocardial infarction. In addition, the myocardial infarction-induced inflammatory response was similar in vitamin D receptor mutants and wild-type mice, as evidenced by a comparable upregulation in cardiac interleukin-1-β and tumor-necrosis-factor-α mRNA abundance and similar elevations in circulating interleukin-1-β and tumor-necrosis-factor-α. Our data suggest that the lack of vitamin D signalling in normocalcaemic vitamin D receptor mutants has no major detrimental effect on cardiac function and outcome post-myocardial infarction. Our study may have important clinical implications because it suggests that the secondary hyperparathyroidism induced by vitamin D deficiency, rather than the lack of vitamin D signalling per se, may negatively impact cardiac function post-myocardial infarction.
Collapse
Affiliation(s)
- Kristopher Ford
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Nejla Latic
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Svetlana Slavic
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Ute Zeitz
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Marlies Dolezal
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Oleh Andrukhov
- Division of Conservative Dentistry and Periodontology, School of Dentistry, Medical University of Vienna, Vienna, Austria
| | - Reinhold G. Erben
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
- * E-mail:
| | - Olena Andrukhova
- Dept. of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
20
|
Slavic S, Andrukhova O, Ford K, Handschuh S, Latic N, Reichart U, Sasgary S, Bergow C, Hofbauer LC, Kostenuik PJ, Erben RG. Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. J Mol Med (Berl) 2018; 96:559-573. [PMID: 29736604 PMCID: PMC5988763 DOI: 10.1007/s00109-018-1641-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 04/18/2018] [Accepted: 04/22/2018] [Indexed: 12/13/2022]
Abstract
The RANK (receptor activator of nuclear factor κB)/RANKL (RANK ligand)/OPG (osteoprotegerin) axis is activated after myocardial infarction (MI), but its pathophysiological role is not well understood. Here, we investigated how global and cell compartment-selective inhibition of RANKL affects cardiac function and remodeling after MI in mice. Global RANKL inhibition was achieved by treatment of human RANKL knock-in (huRANKL-KI) mice with the monoclonal antibody AMG161. huRANKL-KI mice express a chimeric RANKL protein wherein part of the RANKL molecule is humanized. AMG161 inhibits human and chimeric but not murine RANKL. To dissect the pathophysiological role of RANKL derived from hematopoietic and mesenchymal cells, we selectively exchanged the hematopoietic cell compartment by lethal irradiation and across-genotype bone marrow transplantation between wild-type and huRANKL-KI mice, exploiting the specificity of AMG161. After permanent coronary artery ligation, mice were injected with AMG161 or an isotype control antibody over 4 weeks post-MI. MI increased RANKL expression mainly in cardiomyocytes and scar-infiltrating cells 4 weeks after MI. Only inhibition of RANKL derived from hematopoietic cellular sources, but not global or mesenchymal RANKL inhibition, improved post-infarct survival and cardiac function. Mechanistically, hematopoietic RANKL inhibition reduced expression of the pro-inflammatory cytokine IL-1ß in the cardiac cellular infiltrate. In conclusion, inhibition of RANKL derived from hematopoietic cellular sources is beneficial to maintain post-ischemic cardiac function by reduction of pro-inflammatory cytokine production. KEY MESSAGES: Experimental myocardial infarction (MI) augments cardiac RANKL expression in mice. RANKL expression is increased in cardiomyocytes and scar-infiltrating cells after MI. Global or mesenchymal cell RANKL inhibition has no influence on cardiac function after MI. Inhibition of RANKL derived from hematopoietic cells improves heart function post-MI. Hematopoietic RANKL inhibition reduces pro-inflammatory cytokines in scar-infiltrating cells.
Collapse
Affiliation(s)
- Svetlana Slavic
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - Olena Andrukhova
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - Kristopher Ford
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | | | - Nejla Latic
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - Ursula Reichart
- VetCore, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Soleman Sasgary
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - Claudia Bergow
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria
| | - Lorenz C Hofbauer
- Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
| | - Paul J Kostenuik
- Amgen Inc., Thousand Oaks, CA, USA
- Phylon Pharma Services, Newbury Park, CA, USA
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210, Vienna, Austria.
| |
Collapse
|
21
|
Andrukhova O, Schüler C, Bergow C, Petric A, Erben RG. Augmented Fibroblast Growth Factor-23 Secretion in Bone Locally Contributes to Impaired Bone Mineralization in Chronic Kidney Disease in Mice. Front Endocrinol (Lausanne) 2018; 9:311. [PMID: 29942284 PMCID: PMC6004378 DOI: 10.3389/fendo.2018.00311] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 05/24/2018] [Indexed: 11/13/2022] Open
Abstract
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism caused by CKD. Impaired bone mineralization together with increased bony secretion of fibroblast growth factor-23 (FGF23) are hallmarks of CKD-MBD. We recently showed that FGF23 suppresses the expression of tissue nonspecific alkaline phosphatase (TNAP) in bone cells by a Klotho-independent, FGF receptor-3-mediated signaling axis, leading to the accumulation of the mineralization inhibitor pyrophosphate. Therefore, we hypothesized that excessive FGF23 secretion may locally impair bone mineralization in CKD-MBD. To test this hypothesis, we induced CKD by 5/6 nephrectomy in 3-month-old wild-type (WT) mice and Fgf23-/-/VDRΔ/Δ (Fgf23/VDR) compound mutant mice maintained on a diet enriched with calcium, phosphate, and lactose. Eight weeks postsurgery, WT CKD mice were characterized by reduced bone mineral density at the axial and appendicular skeleton, hyperphosphatemia, secondary hyperparathyroidism, increased serum intact Fgf23, and impaired bone mineralization as evidenced by bone histomorphometry. Laser capture microdissection in bone cryosections showed that both osteoblasts and osteocytes contributed to the CKD-induced increase in Fgf23 mRNA abundance. In line with our hypothesis, osteoblastic and osteocytic activity of alkaline phosphatase was reduced, and bone pyrophosphate concentration was ~2.5-fold higher in CKD mice, relative to Sham controls. In Fgf23/VDR compound mice lacking Fgf23, 5/6-Nx induced secondary hyperparathyroidism and bone loss. However, 5/6-Nx failed to suppress TNAP activity, and bone pyrophosphate concentrations remained unchanged in Fgf23/VDR CKD mice. Collectively, our data suggest that elevated Fgf23 production in bone contributes to the mineralization defect in CKD-MBD by auto-/paracrine suppression of TNAP and subsequent accumulation of pyrophosphate in bone. Hence, our study has identified a novel mechanism involved in the pathogenesis of CKD-MBD.
Collapse
Affiliation(s)
- Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Christiane Schüler
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Claudia Bergow
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Alexandra Petric
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
22
|
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone suppressing phosphate reabsorption and vitamin D hormone synthesis in the kidney. At physiological concentrations of the hormone, the endocrine actions of FGF23 in the kidney are αKlotho-dependent, because high-affinity binding of FGF23 to FGF receptors requires the presence of the co-receptor αKlotho on target cells. It is well established that excessive concentrations of intact FGF23 in the blood lead to phosphate wasting in patients with normal kidney function. Based on the importance of diseases associated with gain of FGF23 function such as phosphate-wasting diseases and chronic kidney disease, a large body of literature has focused on the pathophysiological consequences of FGF23 excess. Less emphasis has been put on the role of FGF23 in normal physiology. Nevertheless, during recent years, lessons we have learned from loss-of-function models have shown that besides the paramount physiological roles of FGF23 in the control of 1α-hydroxylase expression and of apical membrane expression of sodium-phosphate co-transporters in proximal renal tubules, FGF23 also is an important stimulator of calcium and sodium reabsorption in distal renal tubules. In addition, there is an emerging role of FGF23 as an auto-/paracrine regulator of alkaline phosphatase expression and mineralization in bone. In contrast to the renal actions of FGF23, the FGF23-mediated suppression of alkaline phosphatase in bone is αKlotho-independent. Moreover, FGF23 may be a physiological suppressor of differentiation of hematopoietic stem cells into the erythroid lineage in the bone microenvironment. At present, there is little evidence for a physiological role of FGF23 in organs other than kidney and bone. The purpose of this mini-review is to highlight the current knowledge about the complex physiological functions of FGF23.
Collapse
|
23
|
Zwolanek D, Satué M, Proell V, Godoy JR, Odörfer KI, Flicker M, Hoffmann SC, Rülicke T, Erben RG. Tracking mesenchymal stem cell contributions to regeneration in an immunocompetent cartilage regeneration model. JCI Insight 2017; 2:87322. [PMID: 29046476 DOI: 10.1172/jci.insight.87322] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 09/20/2017] [Indexed: 01/22/2023] Open
Abstract
It is currently controversially discussed whether mesenchymal stem cells (MSC) facilitate cartilage regeneration in vivo by a progenitor- or a nonprogenitor-mediated mechanism. Here, we describe a potentially novel unbiased in vivo cell tracking system based on transgenic donor and corresponding immunocompetent marker-tolerant recipient mouse and rat lines in inbred genetic backgrounds. Tolerance of recipients was achieved by transgenic expression of an immunologically neutral but physicochemically distinguishable variant of the marker human placental alkaline phosphatase (ALPP). In this dual transgenic system, donor lines ubiquitously express WT, heat-resistant ALPP protein, whereas recipient lines express a heat-labile ALPP mutant (ALPPE451G) resulting from a single amino acid substitution. Tolerance of recipient lines to ALPP-expressing cells and tissues was verified by skin transplantation. Using this model, we show that intraarticularly injected MSC contribute to regeneration of articular cartilage in full-thickness cartilage defects mainly via a nonprogenitor-mediated mechanism.
Collapse
Affiliation(s)
- Daniela Zwolanek
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - María Satué
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Verena Proell
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - José R Godoy
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Kathrin I Odörfer
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Magdalena Flicker
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Sigrid C Hoffmann
- Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Thomas Rülicke
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
24
|
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone, mainly produced by osteoblasts and osteocytes in response to increased extracellular phosphate and circulating vitamin D hormone. Endocrine FGF23 signaling requires co-expression of the ubiquitously expressed FGF receptor 1 (FGFR1) and the co-receptor α-Klotho (Klotho). In proximal renal tubules, FGF23 suppresses the membrane expression of the sodium-phosphate cotransporters Npt2a and Npt2c which mediate urinary reabsorption of filtered phosphate. In addition, FGF23 suppresses proximal tubular expression of 1α-hydroxylase, the key enzyme responsible for vitamin D hormone production. In distal renal tubules, FGF23 signaling activates with-no-lysine kinase 4, leading to increased renal tubular reabsorption of calcium and sodium. Therefore, FGF23 is not only a phosphaturic but also a calcium- and sodium-conserving hormone, a finding that may have important implications for the pathophysiology of chronic kidney disease. Besides these endocrine, Klotho-dependent functions of FGF23, FGF23 is also an auto-/paracrine suppressor of tissue-nonspecific alkaline phosphatase transcription via Klotho-independent FGFR3 signaling, leading to local inhibition of mineralization through accumulation of pyrophosphate. In addition, FGF23 may target the heart via an FGFR4-mediated Klotho-independent signaling cascade. Taken together, there is emerging evidence that FGF23 is a pleiotropic hormone, linking bone with several other organ systems.
Collapse
MESH Headings
- Autocrine Communication
- Bone and Bones/physiology
- Calcification, Physiologic
- Cardiovascular System
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors/physiology
- Glucuronidase/physiology
- Humans
- Immunomodulation
- Kidney Tubules, Proximal/physiology
- Klotho Proteins
- Paracrine Communication
- Phosphates/physiology
- Receptor, Fibroblast Growth Factor, Type 1/physiology
- Receptor, Fibroblast Growth Factor, Type 3/physiology
- Receptor, Fibroblast Growth Factor, Type 4/physiology
- Sodium-Phosphate Cotransporter Proteins, Type IIa/physiology
- Sodium-Phosphate Cotransporter Proteins, Type IIc/physiology
Collapse
Affiliation(s)
- Reinhold G Erben
- 1 Department of Biomedical Sciences, Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
25
|
Andrukhova O, Bayer J, Schüler C, Zeitz U, Murali SK, Ada S, Alvarez-Pez JM, Smorodchenko A, Erben RG. Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis. J Bone Miner Res 2017; 32:2049-2061. [PMID: 28600880 DOI: 10.1002/jbmr.3195] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 05/30/2017] [Accepted: 06/09/2017] [Indexed: 12/30/2022]
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone regulating vitamin D hormone production and renal handling of minerals by signaling through an FGF receptor/αKlotho (Klotho) receptor complex. Whether Klotho has FGF23-independent effects on mineral homeostasis is a controversial issue. Here, we aimed to shed more light on this controversy by comparing male and female triple knockout mice with simultaneous deficiency in Fgf23 and Klotho and a nonfunctioning vitamin D receptor (VDR) (Fgf23/Klotho/VDR) with double (Fgf23/VDR, Klotho/VDR, and Fgf23/Klotho) and single Fgf23, Klotho, and VDR mutants. As expected, 4-week-old Fgf23, Klotho, and Fgf23/Klotho knockout mice were hypercalcemic and hyperphosphatemic, whereas VDR, Fgf23/VDR, and Klotho/VDR mice on rescue diet were normocalcemic and normophosphatemic. Serum levels of calcium, phosphate, and sodium did not differ between 4-week-old triple Fgf23/Klotho/VDR and double Fgf23/VDR or Klotho/VDR knockout mice. Notably, 3-month-old Fgf23/Klotho/VDR triple knockout mice were indistinguishable from double Fgf23/VDR and Klotho/VDR compound mutants in terms of serum calcium, serum phosphate, serum sodium, and serum PTH, as well as urinary calcium and sodium excretion. Protein expression analysis revealed increased membrane abundance of sodium-phosphate co-transporter 2a (NaPi-2a), and decreased expression of sodium-chloride co-transporter (NCC) and transient receptor potential cation channel subfamily V member 5 (TRPV5) in Fgf23/Klotho/VDR, Fgf23/VDR, and Klotho/VDR mice, relative to wild-type and VDR mice, but no differences between triple and double knockouts. Further, ex vivo treatment of live kidney slices isolated from wild-type and Klotho/VDR mice with soluble Klotho did not induce changes in intracellular phosphate, calcium or sodium accumulation assessed by two-photon microscopy. In conclusion, our data suggest that the main physiological function of Klotho for mineral homeostasis in vivo is its role as co-receptor mediating Fgf23 action. © 2017 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Jessica Bayer
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Christiane Schüler
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Ute Zeitz
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Sathish K Murali
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Sibel Ada
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| | | | - Alina Smorodchenko
- Institute for Vegetative Anatomy, Charité University of Berlin, Berlin, Germany
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
26
|
Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG. Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. Sci Rep 2017; 7:6460. [PMID: 28744019 PMCID: PMC5527119 DOI: 10.1038/s41598-017-06614-0] [Citation(s) in RCA: 121] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 06/14/2017] [Indexed: 12/21/2022] Open
Abstract
Estrogen is critical for skeletal homeostasis and regulates bone remodeling, in part, by modulating the expression of receptor activator of NF-κB ligand (RANKL), an essential cytokine for bone resorption by osteoclasts. RANKL can be produced by a variety of hematopoietic (e.g. T and B-cell) and mesenchymal (osteoblast lineage, chondrocyte) cell types. The cellular mechanisms by which estrogen acts on bone are still a matter of controversy. By using murine reconstitution models that allow for selective deletion of estrogen receptor-alpha (ERα) or selective inhibition of RANKL in hematopoietic vs. mesenchymal cells, in conjunction with in situ expression profiling in bone cells, we identified bone lining cells as important gatekeepers of estrogen-controlled bone resorption. Our data indicate that the increase in bone resorption observed in states of estrogen deficiency in mice is mainly caused by lack of ERα-mediated suppression of RANKL expression in bone lining cells.
Collapse
Affiliation(s)
- Carmen Streicher
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Alexandra Heyny
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Olena Andrukhova
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Barbara Haigl
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Svetlana Slavic
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Christiane Schüler
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Karoline Kollmann
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Ingrid Kantner
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
- UCB Pharma GmbH, Vienna, Austria
| | - Veronika Sexl
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Miriam Kleiter
- Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Lorenz C Hofbauer
- Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
| | - Paul J Kostenuik
- Amgen Inc., Thousand Oaks, CA, USA
- Phylon Pharma Services, Newbury Park, CA, USA
| | - Reinhold G Erben
- Department of Biomedical Research, University of Veterinary Medicine Vienna, Vienna, Austria.
| |
Collapse
|
27
|
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone protecting against the potentially deleterious effects of hyperphosphatemia by suppression of phosphate reabsorption and of active vitamin D hormone synthesis in the kidney. The kidney is one of the main target organs of FGF23 signaling. The purpose of this review is to highlight the recent advances in the area of FGF23-Klotho signaling in the kidney. During recent years, it has become clear that FGF23 acts independently on proximal and distal tubular epithelium. In proximal renal tubules, FGF23 suppresses phosphate reabsorption by a Klotho dependent activation of extracellular signal-regulated kinase-1/2 (ERK1/2) and of serum/glucocorticoid-regulated kinase-1 (SGK1), leading to phosphorylation of the scaffolding protein Na+/H+ exchange regulatory cofactor (NHERF)-1 and subsequent internalization and degradation of sodium-phosphate cotransporters. In distal renal tubules, FGF23 augments calcium and sodium reabsorption by increasing the apical membrane expression of the epithelial calcium channel TRPV5 and of the sodium-chloride cotransporter NCC through a Klotho dependent activation of with-no-lysine kinase-4 (WNK4). In proximal and distal renal tubules, FGF receptor-1 is probably the dominant FGF receptor mediating the effects of FGF23 by forming a complex with membrane-bound Klotho in the basolateral membrane. The newly described sodium- and calcium-conserving functions of FGF23 may have major implications for the pathophysiology of diseases characterized by chronically increased circulating FGF23 concentrations such as chronic kidney disease.
Collapse
|
28
|
Knab VM, Corbin B, Andrukhova O, Hum JM, Ni P, Rabadi S, Maeda A, White KE, Erben RG, Jüppner H, Christov M. Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. Endocrinology 2017; 158:1130-1139. [PMID: 28324013 PMCID: PMC5460828 DOI: 10.1210/en.2016-1451] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Accepted: 01/12/2017] [Indexed: 12/18/2022]
Abstract
The acute effects of parathyroid hormone (PTH) on fibroblast growth factor 23 (FGF23) in vivo are not well understood. After a single subcutaneous PTH (1-34) injection (50 nmol/kg) in mice, FGF23 levels were assessed in plasma using assays that measure either intact alone (iFGF23) or intact/C-terminal FGF23 (cFGF23). Furthermore, FGF23 messenger RNA (mRNA) and protein levels were assessed in bone. In addition, we examined the effects of PTH treatment on FGF23 production in vitro using differentiated calvarial osteocyte-like cells. cFGF23 levels increased by three- to fivefold within 2 hours following PTH injection, which returned to baseline by 4 hours. In contrast, iFGF23 levels remained unchanged for the first 2 hours, yet declined to ∼60% by 6 hours and remained suppressed before returning to baseline after 24 hours. Using homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection. These findings are consistent with increased FGF23 production in bone, yet rapid cleavage of the secreted intact protein. Using primary osteocyte-like cell cultures, we showed that PTH increased FGF23 mRNA expression through cyclic adenosine monophosphate/protein kinase A, but not inositol triphosphate/protein kinase C signaling; PTH also increased furin protein levels. In conclusion, PTH injection rapidly increases FGF23 production in bone in vivo and in vitro. However, iFGF23 is rapidly degraded. At later time points through an unidentified mechanism, a sustained decrease in FGF23 production occurs.
Collapse
Affiliation(s)
- Vanessa M Knab
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114
- Department of Biomedical Sciences, University of Veterinary Medicine, A-1210 Vienna, Austria
| | - Braden Corbin
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114
| | - Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine, A-1210 Vienna, Austria
| | - Julia M Hum
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202
| | - Pu Ni
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202
| | - Seham Rabadi
- Department of Medicine, New York Medical College, Valhalla, New York 10595
| | - Akira Maeda
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114
| | - Kenneth E White
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, A-1210 Vienna, Austria
| | - Harald Jüppner
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114
| | - Marta Christov
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114
- Department of Medicine, New York Medical College, Valhalla, New York 10595
| |
Collapse
|
29
|
Nebot E, Aparicio VA, Pietschmann P, Camiletti-Moirón D, Kapravelou G, Erben RG, Martínez R, Sánchez-González C, Porres JM, Llopis J, López-Jurado M, Aranda P. Effects of Hypertrophy Exercise in Bone Turnover Markers and Structure in Growing Male Rats. Int J Sports Med 2017; 38:418-425. [PMID: 28388781 DOI: 10.1055/s-0043-101910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The benefits of exercise on bone density, structure and turnover markers are rather controversial. The present study aimed to examine the effects of hypertrophy exercise (HE) on bone. 20 male Wistar rats were randomly distributed in 2 experimental groups, one performing HE and the other untrained over 12 weeks. Plasma parameters, bone mineral content, bone mineral density (BMD), structure, and trabecular and cortical microarchitecture were measured. Femur Mg content was 12% higher (p<0.001), whereas femur length, dry weight, P content, and aminoterminal propeptides of type I procollagen were lower in the HE group (all, p<0.05). Total BMD and cortical/subcortical BMD were higher (both, p<0.01), whereas total cross-sectional and trabecular areas were lower (both, p<0.001), and cortical area and thickness were lower in the HE (both, p<0.05). Trabecular connectivity density, number, mean density of total and bone volume were higher in the HE (all, p<0.05). Cortical volume fraction and the mean density of total volume of the diaphysis were lower, whereas the cortical volume density was higher in the HE (all, p<0.05). This HE protocol may have beneficial effect on cancellous bone microarchitecture, but it induces low bone formation and is associated with hypogonadism in growing male rats. However, this type of training might be inefficient to maintain appropriate cortical thickness.
Collapse
Affiliation(s)
- Elena Nebot
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain.,Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
| | - Virginia A Aparicio
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain.,Department of Public and Occupational Health, EMGO+ Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands
| | - Peter Pietschmann
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
| | - Daniel Camiletti-Moirón
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain.,Department of Physical Education, Faculty of Education Sciences, University of Cádiz, Cádiz, Spain
| | - Garyfallia Kapravelou
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain
| | - Reinhold G Erben
- Department of Biomedical Sciences, Institute of Physiology, Pathophysiology, and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Rosario Martínez
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain
| | | | - Jesús M Porres
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain
| | - Juan Llopis
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain
| | | | - Pilar Aranda
- CIBM, IMUDS, Department of Physiology, School of Pharmacy, University of Granada, Spain
| |
Collapse
|
30
|
Kaludjerovic J, Komaba H, Sato T, Erben RG, Baron R, Olauson H, Larsson TE, Lanske B. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J 2017; 31:2050-2064. [PMID: 28183805 DOI: 10.1096/fj.201601036r] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 01/17/2017] [Indexed: 12/24/2022]
Abstract
Circulating levels of bone-derived fibroblast growth factor 23 (FGF23) increase early during acute and chronic kidney disease and are associated with adverse outcomes. Membrane-bound Klotho acts as a permissive coreceptor for FGF23, and its expression was recently found in osteoblasts/osteocytes. We hypothesized that Klotho in bone cells is part of an autocrine feedback loop that regulates FGF23 expression during renal failure. Thus, we induced renal failure in mice with targeted deletion of Klotho in long bones. Uremic wild-type (KLfl/fl ) and knockout (Prx1-Cre;KLfl/fl ) mice both responded with reduced body weight, kidney atrophy, hyperphosphatemia, and increased bone turnover. Importantly, long bones of Prx1-Cre;KLfl/fl mice but not their axial skeleton failed to increase FGF23 expression as observed in uremic KLfl/fl mice. Consequently, Prx1-Cre;KLfl/fl mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-α-hydroxylase expression, serum 1,25-dihydroxyvitamin D, and calcium levels than KLfl/fl mice. These results were confirmed in two independent models of renal failure, adenine diet induced and 5/6 nephrectomy. Moreover, FGF23-treated bone cells required Klotho to increase FGF23 mRNA and ERK phosphorylation. In summary, our novel findings show that Klotho in bone is crucial for inducing FGF23 production upon renal failure. We propose the presence of an autocrine feedback loop in which Klotho senses the need for FGF23.-Kaludjerovic, J., Komaba, H., Sato, T., Erben, R. G., Baron, R., Olauson, H., Larsson, T. E., Lanske, B. Klotho expression in long bones regulates FGF23 production during renal failure.
Collapse
Affiliation(s)
- Jovana Kaludjerovic
- Division of Bone and Mineral Research, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA
| | - Hirotaka Komaba
- Division of Bone and Mineral Research, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA
| | - Tadatoshi Sato
- Division of Bone and Mineral Research, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA
| | - Reinhold G Erben
- Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria
| | - Roland Baron
- Division of Bone and Mineral Research, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.,Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Hannes Olauson
- Division of Renal Medicine, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Tobias E Larsson
- Division of Renal Medicine, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Beate Lanske
- Division of Bone and Mineral Research, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; .,Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
31
|
Smorodchenko A, Schneider S, Rupprecht A, Hilse K, Sasgary S, Zeitz U, Erben RG, Pohl EE. UCP2 up-regulation within the course of autoimmune encephalomyelitis correlates with T-lymphocyte activation. Biochim Biophys Acta Mol Basis Dis 2017; 1863:1002-1012. [PMID: 28130201 DOI: 10.1016/j.bbadis.2017.01.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2016] [Revised: 01/07/2017] [Accepted: 01/23/2017] [Indexed: 01/20/2023]
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disorder of the central nervous system (CNS) associated with severe neurological disability. Reactive oxygen species (ROS) and mitochondrial dysfunction play a pivotal role in the pathogenesis of this disease. Several members of the mitochondrial uncoupling protein subfamily (UCP2-UCP5) were suggested to regulate ROS by diminishing the mitochondrial membrane potential and constitute therefore a promising pharmacological target for MS. To evaluate the role of different uncoupling proteins in neuroinflammation, we have investigated their expression patterns in murine brain and spinal cord (SC) during different stages of experimental autoimmune encephalomyelitis (EAE), an animal model for MS. At mRNA and protein levels we found that only UCP2 is up-regulated in the SC, but not in brain. The increase in UCP2 expression was antigen-independent, reached its maximum between 14 and 21days in both OVA and MOG immunized animals and correlated with an augmented number of CD3+ T-lymphocytes in SC parenchyma. The decrease in abundance of UCP4 was due to neuronal injury and was only detected in CNS of MOG-induced EAE animals. The results provide evidence that the involvement of mitochondrial UCP2 in CNS inflammation during EAE may be mainly explained by the invasion of activated T-lymphocytes. This conclusion coincides with our previous observation that UCP2 is up-regulated in activated and rapidly proliferating T-cells and participates in fast metabolic re-programming of cells during proliferation.
Collapse
Affiliation(s)
- Alina Smorodchenko
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria; Institute of Vegetative Anatomy, Charité - Universitätsmedizin Berlin, Germany.
| | - Stephanie Schneider
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Anne Rupprecht
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Karoline Hilse
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Soleman Sasgary
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Ute Zeitz
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - Elena E Pohl
- Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, Vienna, Austria.
| |
Collapse
|
32
|
Andrukhova O, Streicher C, Zeitz U, Erben RG. Fgf23 and parathyroid hormone signaling interact in kidney and bone. Mol Cell Endocrinol 2016; 436:224-39. [PMID: 27498418 DOI: 10.1016/j.mce.2016.07.035] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 07/26/2016] [Accepted: 07/26/2016] [Indexed: 12/19/2022]
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone, suppressing renal phosphate reabsorption and vitamin D hormone synthesis in proximal tubules, and stimulating calcium reabsorption in distal tubules of the kidney. Here, we analyzed the long term sequelae of deficient Fgf23 signaling on bone and mineral metabolism in 9-month-old mice lacking both Fgf23 or Klotho and a functioning vitamin D receptor (VDR). To prevent hypocalcemia in VDR deficient mice, all mice were kept on a rescue diet enriched with calcium, phosphate, and lactose. VDR mutants were normocalcemic and normophosphatemic, and had normal tibial bone mineral density. Relative to VDR mutants, Fgf23/VDR and Klotho/VDR compound mutants were characterized by hypocalcemia, hyperphosphatemia, and very high serum parathyroid hormone (PTH). Despite ∼10-fold higher serum PTH levels in compound mutants, urinary excretion of phosphate and calcium as well as osteoclast numbers in bone remained unchanged relative to VDR mutants. The increase in plasma cAMP after hPTH(1-34) injection was similar in all genotypes. However, a 5-day infusion of hPTH(1-34) via osmotic minipumps resulted in reduced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) in bone and kidney of Fgf23/VDR and Klotho/VDR compound mutants, relative to VDR and WT controls. Similarly, the PTH-mediated ERK1/2 phosphorylation was reduced in primary osteoblasts isolated from Fgf23 and Klotho deficient mice, but was restored by concomitant treatment with recombinant FGF23. Collectively, our data indicate that the phosphaturic, calcium-conserving, and bone resorption-stimulating actions of PTH are blunted by Fgf23 or Klotho deficiency. Hence, FGF23 may be an important modulator of PTH signaling in bone and kidney.
Collapse
Affiliation(s)
- Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine, 1210, Vienna, Austria
| | - Carmen Streicher
- Department of Biomedical Sciences, University of Veterinary Medicine, 1210, Vienna, Austria
| | - Ute Zeitz
- Department of Biomedical Sciences, University of Veterinary Medicine, 1210, Vienna, Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, 1210, Vienna, Austria.
| |
Collapse
|
33
|
Mosti MP, Ericsson M, Erben RG, Schüler C, Syversen U, Stunes AK. The PPARα Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats. Endocrinology 2016; 157:3924-3934. [PMID: 27526032 DOI: 10.1210/en.2016-1114] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The musculoskeletal effects of exercise are attenuated by estrogen deficiency. The peroxisome proliferator-activated receptor-α agonist fenofibrate exerts beneficial effects in bone and muscle. We therefore examined whether fenofibrate could enhance the musculoskeletal training response during estrogen deficiency. We investigated the combined effects of 8 weeks of fenofibrate and jumping exercise in ovariectomized (OVX) Sprague Dawley rats. Female rats were allocated to a sham-operated group and four OVX groups; fenofibrate (OVX-Fen), exercise (OVX-Ex), combined fenofibrate and exercise (OVX-FenEx), and a control group (OVX-Ctr) (n = 12/group). Fenofibrate (90 mg/kg/d) or methylcellulose was given by gavage. The combination of exercise and fenofibrate resulted in enhanced femoral bone mineral density (BMD) and improved bone microarchitecture compared with fenofibrate alone as well as increased trabecular BMD compared with OVX-Ctr. These effects were not seen in the OVX-Ex group. Femoral BMD was normalized in both exercise groups relative to sham and increased more in all intervention groups compared with OVX-Ctr. A higher plasma level of the bone formation marker type 1 collagen amino propeptide was observed in the OVX-Fen and OVX-FenEx groups compared with controls. Lean mass and soleus muscle weight were higher in the OVX-FenEx group than in the OVX-Ctr group, which coincided with lower mRNA levels of Atrogin1. These results suggest that peroxisome proliferator-activated receptor-α activation improves the musculoskeletal effects of exercise during estrogen deficiency.
Collapse
Affiliation(s)
- Mats Peder Mosti
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| | - Madelene Ericsson
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| | - Reinhold G Erben
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| | - Christiane Schüler
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| | - Unni Syversen
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| | - Astrid Kamilla Stunes
- Department of Cancer Research and Molecular Medicine (M.P.M., U.S., A.K.S.), Norwegian University of Science and Technology, N-7491 Trondheim, Norway; Department of Medical Biosciences and Physiological Chemistry (M.E.), Umeå University, SE-901 87 Umeå, Sweden; and Department of Biomedical Sciences (R.G.E., C.S.), University of Veterinary Medicine Vienna, A-1210 Vienna, Austria; and Department of Endocrinology (U.S.), St Olav's University Hospital HF, N-7006 Trondheim, Norway
| |
Collapse
|
34
|
Abstract
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone known to suppress phosphate reabsorption and vitamin D hormone production in the kidney. Klotho was originally discovered as an anti-aging factor, but the functional role of Klotho is still a controversial issue. Three major functions have been proposed, a hormonal function of soluble Klotho, an enzymatic function as glycosidase, and the function as an obligatory co-receptor for FGF23 signaling. The purpose of this review is to highlight the recent advances in the area of FGF23 and Klotho signaling in the kidney, in the parathyroid gland, in the cardiovascular system, in bone, and in the central nervous system. During recent years, major new functions of FGF23 and Klotho have been discovered in these organ systems. Based on these novel findings, FGF23 has emerged as a pleiotropic endocrine and auto-/paracrine factor influencing not only mineral metabolism but also cardiovascular function.
Collapse
|
35
|
Aasarød KM, Ramezanzadehkoldeh M, Shabestari M, Mosti MP, Stunes AK, Reseland JE, Beisvag V, Eriksen EF, Sandvik AK, Erben RG, Schüler C, Boyce M, Skallerud BH, Syversen U, Fossmark R. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice. J Endocrinol 2016; 230:251-62. [PMID: 27325243 DOI: 10.1530/joe-16-0017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 06/20/2016] [Indexed: 12/15/2022]
Abstract
Epidemiological studies suggest an increased fracture risk in patients taking proton pump inhibitors (PPIs) for long term. The underlying mechanism, however, has been disputed. By binding to the gastric proton pump, PPIs inhibit gastric acid secretion. We have previously shown that proton pump (H(+)/K(+)ATPase beta subunit) KO mice exhibit reduced bone mineral density (BMD) and inferior bone strength compared with WT mice. Patients using PPIs as well as these KO mice exhibit gastric hypoacidity, and subsequently increased serum concentrations of the hormone gastrin. In this study, we wanted to examine whether inhibition of the gastrin/CCK2 receptor influences bone quality in these mice. KO and WT mice were given either the gastrin/CCK2 receptor antagonist netazepide dissolved in polyethylene glycol (PEG) or only PEG for 1year. We found significantly lower bone mineral content and BMD, as well as inferior bone microarchitecture in KO mice compared with WT. Biomechanical properties by three-point bending test also proved inferior in KO mice. KO mice receiving netazepide exhibited significantly higher cortical thickness, cortical area fraction, trabecular thickness and trabecular BMD by micro-CT compared with the control group. Three-point bending test also showed higher Young's modulus of elasticity in the netazepide KO group compared with control mice. In conclusion, we observed that the gastrin receptor antagonist netazepide slightly improved bone quality in this mouse model, suggesting that hypergastrinemia may contribute to deteriorated bone quality during acid inhibition.
Collapse
Affiliation(s)
- Kristin M Aasarød
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway
| | | | - Maziar Shabestari
- Department of BiomaterialsInstitute of Clinical Dentistry, University of Oslo, Oslo, Norway
| | - Mats P Mosti
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway
| | - Astrid K Stunes
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway
| | - Janne E Reseland
- Department of BiomaterialsInstitute of Clinical Dentistry, University of Oslo, Oslo, Norway
| | - Vidar Beisvag
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway
| | | | - Arne K Sandvik
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway Department of Gastroenterology and HepatologySt. Olav's Hospital, Trondheim, Norway Centre of Molecular Inflammation ResearchNTNU, Trondheim, Norway
| | - Reinhold G Erben
- Department of Biomedical SciencesUniversity of Veterinary Medicine Vienna, Vienna, Austria
| | - Christiane Schüler
- Department of Biomedical SciencesUniversity of Veterinary Medicine Vienna, Vienna, Austria
| | | | | | - Unni Syversen
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway Department of EndocrinologySt. Olav's Hospital, Trondheim, Norway
| | - Reidar Fossmark
- Department of Cancer Research and Molecular MedicineNTNU, Trondheim, Norway Department of Gastroenterology and HepatologySt. Olav's Hospital, Trondheim, Norway
| |
Collapse
|
36
|
Ford K, Slavic S, Zeitz U, Dolezal M, Erben RG, Andrukhova O. 193 Lack of Fibroblast Growth factor-23 (FGF23) Preserves Cardiac Function in a Murine Model of Acute Myocardial Infarction. Heart 2016. [DOI: 10.1136/heartjnl-2016-309890.193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
37
|
Nebot E, Aparicio VA, Camiletti-Moirón D, Martinez R, Erben RG, Kapravelou G, Sánchez-González C, De Teresa C, Porres JM, López-Jurado M, Aranda P, Pietschmann P. Stanozolol Decreases Bone Turnover Markers, Increases Mineralization, and Alters Femoral Geometry in Male Rats. Calcif Tissue Int 2016; 98:609-18. [PMID: 26801156 DOI: 10.1007/s00223-016-0108-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 01/05/2016] [Indexed: 10/22/2022]
Abstract
Stanozonol (ST) is a synthetic derivative of testosterone; it has anabolic/androgenic activity, increasing both the turnover of trabecular bone and the endocortical apposition of bone. The present study aimed to examine the effects of ST on bone status in rats by bone mineral content, markers of formation and resorption, bone density, and structural and microarchitectural parameters. Twenty male Wistar rats were randomly distributed into two experimental groups corresponding to placebo or ST administration, which consisted of weekly intramuscular injections of 10 mg/kg body weight of ST. Plasma parameters were analyzed by immunoassay. Bone mineral content was determined by spectrophotometry. Bone mineral density (BMD) and structural parameters were measured by peripheral quantitative computed tomography, and trabecular and cortical microarchitecture by micro-computed tomography. Plasma Ca, Mg, and alkaline phosphatase were higher, and urinary Ca excretion, corticosterone, and testosterone concentrations lower in the ST group. Femur Ca content was higher and P content was lower in the ST, whereas osteocalcin, aminoterminal propeptides of type I procollagen, and C-terminal telopeptides of type I collagen were lower. Total cross-sectional, trabecular, and cortical/subcortical areas were lower in the ST. No differences were observed on BMD and area parameters of the diaphysis as well as on trabecular and cortical microarchitecture. The use of ST increases bone mineralization, ash percentage, and Ca and Mg content in femur. In spite of an absence of changes in BMD, geometric metaphyseal changes were observed. We conclude that ST alters bone geometry, leads to low bone turnover, and thus may impair bone quality.
Collapse
Affiliation(s)
- E Nebot
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain.
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
| | - V A Aparicio
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
- Department of Public and Occupational Health, EMGO+ Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands
| | - D Camiletti-Moirón
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
- Department of Physical Education, Faculty of Education Sciences, University of Cádiz, Cádiz, Spain
| | - R Martinez
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - R G Erben
- Department of Biomedical Sciences, Institute of Physiology, Pathophysiology, and Biophysics, University of Veterinary Medicine, Vienna, Austria
| | - G Kapravelou
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - C Sánchez-González
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - C De Teresa
- Andaluzian Sport Medicine Centre, San Juan de Dios Universitary Hospital, Granada, Spain
| | - J M Porres
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - M López-Jurado
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - P Aranda
- Department of Physiology, School of Pharmacy and Institute of Nutrition and Food Technology, University of Granada, Campus universitario de Cartuja s/n, 18071, Granada, Spain
| | - P Pietschmann
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
38
|
Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice. PLoS Biol 2016; 14:e1002427. [PMID: 27035636 PMCID: PMC4818020 DOI: 10.1371/journal.pbio.1002427] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 03/08/2016] [Indexed: 11/24/2022] Open
Abstract
X-linked hypophosphatemia (XLH) is the most frequent form of inherited rickets in humans caused by mutations in the phosphate-regulating gene with homologies to endopeptidases on the X-chromosome (PHEX). Hyp mice, a murine homologue of XLH, are characterized by hypophosphatemia, inappropriately low serum vitamin D levels, increased serum fibroblast growth factor-23 (Fgf23), and osteomalacia. Although Fgf23 is known to be responsible for hypophosphatemia and reduced vitamin D hormone levels in Hyp mice, its putative role as an auto-/paracrine osteomalacia-causing factor has not been explored. We recently reported that Fgf23 is a suppressor of tissue nonspecific alkaline phosphatase (Tnap) transcription via FGF receptor-3 (FGFR3) signaling, leading to inhibition of mineralization through accumulation of the TNAP substrate pyrophosphate. Here, we report that the pyrophosphate concentration is increased in Hyp bones, and that Tnap expression is decreased in Hyp-derived osteocyte-like cells but not in Hyp-derived osteoblasts ex vivo and in vitro. In situ mRNA expression profiling in bone cryosections revealed a ~70-fold up-regulation of Fgfr3 mRNA in osteocytes versus osteoblasts of Hyp mice. In addition, we show that blocking of increased Fgf23-FGFR3 signaling with anti-Fgf23 antibodies or an FGFR3 inhibitor partially restored the suppression of Tnap expression, phosphate production, and mineralization, and decreased pyrophosphate concentration in Hyp-derived osteocyte-like cells in vitro. In vivo, bone-specific deletion of Fgf23 in Hyp mice rescued the suppressed TNAP activity in osteocytes of Hyp mice. Moreover, treatment of wild-type osteoblasts or mice with recombinant FGF23 suppressed Tnap mRNA expression and increased pyrophosphate concentrations in the culture medium and in bone, respectively. In conclusion, we found that the cell autonomous increase in Fgf23 secretion in Hyp osteocytes drives the accumulation of pyrophosphate through auto-/paracrine suppression of TNAP. Hence, we have identified a novel mechanism contributing to the mineralization defect in Hyp mice. A novel mechanism involving autocrine and paracrine actions of fibroblast growth factor-23 contributes to the mineralization defect observed in Hyp, a mouse model for X-linked hypophosphatemia. X-linked hypophosphatemia (XLH) is the most frequent form of inherited rickets in humans. A mouse model of XLH, known as Hyp, is characterized by exceptionally low serum phosphate and vitamin D levels, increased serum levels of the hormone fibroblast growth factor-23 (Fgf23), and impaired bone mineralization. Fgf23 is secreted from two classes of bone cells known as osteoblasts and osteocytes. Fgf23 increases urinary phosphate excretion and suppresses vitamin D hormone production in the kidney. Although Fgf23 is known to be responsible for lower blood phosphate and vitamin D hormone levels in Hyp mice, its putative role as a signaling factor causing impaired mineralization has not been explored. We recently reported that Fgf23 is a suppressor of tissue nonspecific alkaline phosphatase (Tnap) gene expression via FGF receptor-3 (FGFR3) signaling in osteoblasts, leading to inhibition of mineralization through accumulation of the TNAP substrate pyrophosphate. Pyrophosphate is a potent inhibitor of mineralization. Using a combination of cell culture and animal models, we report that the increase in osteocyte Fgf23 secretion of Hyp mice leads to FGFR3-mediated suppression of TNAP with subsequent accumulation of pyrophosphate. Hence, we have identified a novel signaling mechanism by which excessive osteocytic secretion of Fgf23 contributes to the mineralization defect in Hyp mice.
Collapse
Affiliation(s)
- Sathish K. Murali
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Erica L. Clinkenbeard
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Kenneth E. White
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
- * E-mail:
| |
Collapse
|
39
|
Hilse KE, Kalinovich AV, Rupprecht A, Smorodchenko A, Zeitz U, Staniek K, Erben RG, Pohl EE. The expression of UCP3 directly correlates to UCP1 abundance in brown adipose tissue. Biochim Biophys Acta 2016; 1857:72-78. [PMID: 26518386 PMCID: PMC7115856 DOI: 10.1016/j.bbabio.2015.10.011] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 10/16/2015] [Accepted: 10/25/2015] [Indexed: 01/14/2023]
Abstract
UCP1 and UCP3 are members of the uncoupling protein (UCP) subfamily and are localized in the inner mitochondrial membrane. Whereas UCP1's central role in non-shivering thermogenesis is acknowledged, the function and even tissue expression pattern of UCP3 are still under dispute. Because UCP3 properties regarding transport of protons are qualitatively identical to those of UCP1, its expression in brown adipose tissue (BAT) alongside UCP1 requires justification. In this work, we tested whether any correlation exists between the expression of UCP1 and UCP3 in BAT by quantification of protein amounts in mouse tissues at physiological conditions, in cold-acclimated and UCP1 knockout mice. Quantification using recombinant UCP3 revealed that the UCP3 amount in BAT (0.51ng/(μg total tissue protein)) was nearly one order of magnitude higher than that in muscles and heart. Cold-acclimated mice showed an approximate three-fold increase in UCP3 abundance in BAT in comparison to mice in thermoneutral conditions. Surprisingly, we found a significant decrease of UCP3 in BAT of UCP1 knockout mice, whereas the protein amount in skeletal and heart muscles remained constant. UCP3 abundance decreased even more in cold-acclimated UCP1 knockout mice. Protein quantification in UCP3 knockout mice revealed no compensatory increase in UCP1 or UCP2 expression. Our results do not support the participation of UCP3 in thermogenesis in the absence of UCP1 in BAT, but clearly demonstrate the correlation in abundance between both proteins. The latter is important for understanding UCP3's function in BAT.
Collapse
Affiliation(s)
- Karolina E Hilse
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Anastasia V Kalinovich
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Anne Rupprecht
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Alina Smorodchenko
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Ute Zeitz
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Katrin Staniek
- Institute of Pharmacology and Toxicology, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Elena E Pohl
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.
| |
Collapse
|
40
|
Fan Y, Bi R, Densmore MJ, Sato T, Kobayashi T, Yuan Q, Zhou X, Erben RG, Lanske B. Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis. FASEB J 2016; 30:428-40. [PMID: 26428657 PMCID: PMC4684518 DOI: 10.1096/fj.15-278184] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Accepted: 09/14/2015] [Indexed: 02/05/2023]
Abstract
Parathyroid-hormone-type 1 receptor (PTH1R) is extensively expressed in key regulatory organs for systemic mineral ion homeostasis, including kidney and bone. We investigated the bone-specific functions of PTH1R in modulating mineral ion homeostasis by generating a novel mouse model in which PTH1R is ablated in the limb mesenchyme using Prx1Cre transgenic mice. Such ablation decreased FGF23 protein and serum levels by 50%, despite normal Fgf23 mRNA levels in long bones. Circulating calcium and PTH levels were unchanged, but inorganic phosphate and 1,25(OH)2D3 levels were significantly decreased and accompanied by elevated urinary calcium and phosphate wasting. Key renal genes for balancing mineral ion homeostasis, calbindinD28k, Klotho, and Napi2a were suppressed by 30-40%. Intermittent hPTH(1-34) injections increased Fgf23 mRNA (7.3-fold), Nurr1 mRNA (3.1-fold), and serum intact-FGF23 (1.6-fold) in controls, but failed to induce Fgf23, Nurr1 mRNA, or intact FGF23 production in mutants. Moreover, a significant elevation in serum C-terminal-FGF23 levels (4-fold) was detected in both genotypes. PTH markedly downregulated Galnt3 expression (2.7-fold) in controls but not in mutants. These results demonstrate the pivotal role of PTH1R in long bones to regulate systemic mineral ion homeostasis and the direct induction of FGF23 by PTH1R signaling.
Collapse
MESH Headings
- Animals
- Bone and Bones/metabolism
- Calbindins/genetics
- Calbindins/metabolism
- Calcification, Physiologic
- Calcium/blood
- Calcium/metabolism
- Female
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors/genetics
- Fibroblast Growth Factors/metabolism
- Glucuronidase/genetics
- Glucuronidase/metabolism
- Homeostasis
- Kidney/metabolism
- Klotho Proteins
- Male
- Mice
- N-Acetylgalactosaminyltransferases/genetics
- N-Acetylgalactosaminyltransferases/metabolism
- Nuclear Receptor Subfamily 4, Group A, Member 2/genetics
- Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism
- Phosphates/blood
- Phosphates/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, Parathyroid Hormone, Type 1/genetics
- Receptor, Parathyroid Hormone, Type 1/metabolism
- Polypeptide N-acetylgalactosaminyltransferase
Collapse
Affiliation(s)
- Yi Fan
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Ruiye Bi
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Michael J Densmore
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Tadatoshi Sato
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Tatsuya Kobayashi
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Quan Yuan
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Xuedong Zhou
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Beate Lanske
- *Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China; West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China; Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; and Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
41
|
Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG. FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner. J Bone Miner Res 2016; 31:129-42. [PMID: 26235988 DOI: 10.1002/jbmr.2606] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 07/23/2015] [Accepted: 07/24/2015] [Indexed: 12/25/2022]
Abstract
Fibroblast growth factor-23 (Fgf23) is a bone-derived hormone, suppressing phosphate reabsorption and vitamin D hormone (1,25(OH)2 D3 ) production in the kidney. It has long been an enigma why lack of Fgf23 or of Klotho, the coreceptor for Fgf23, leads to severe impairment in bone mineralization despite the presence of hypercalcemia and hyperphosphatemia. Using Fgf23(-/-) or Klotho(-/-) mice together with compound mutant mice lacking both Fgf23 or Klotho and a functioning vitamin D receptor, we show that in Klotho(-/-) mice the mineralization defect is solely driven by 1,25(OH)2 D3 -induced upregulation of the mineralization-inhibiting molecules osteopontin and pyrophosphate in bone. In Fgf23(-/-) mice, the mineralization defect has two components, a 1,25(OH)2 D3 -driven component similar to Klotho(-/-) mice and a component driven by lack of Fgf23, causing additional accumulation of osteopontin. We found that FGF23 regulates osteopontin secretion indirectly by suppressing alkaline phosphatase transcription and phosphate production in osteoblastic cells, acting through FGF receptor-3 in a Klotho-independent manner. Hence, FGF23 secreted from osteocytes may form an autocrine/paracrine feedback loop for the local fine-tuning of bone mineralization.
Collapse
Affiliation(s)
- Sathish Kumar Murali
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Paul Roschger
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria
| | - Ute Zeitz
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Klaus Klaushofer
- Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria
| | - Olena Andrukhova
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
42
|
Jay FF, Vaidya M, Porada SM, Andrukhova O, Schneider MR, Erben RG. Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone. Mol Cell Endocrinol 2015; 417:158-65. [PMID: 26427650 DOI: 10.1016/j.mce.2015.09.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 09/08/2015] [Accepted: 09/26/2015] [Indexed: 02/07/2023]
Abstract
Although parathyroid hormone (PTH) has long been known to act as a bone anabolic agent when administered intermittently, the exact underlying mechanisms remain largely unknown. Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, has been identified to be a PTH target gene in vitro and in vivo. Here, we used female global AREG knockout (AREG-KO) mice to explore the role of AREG in mediating the bone anabolic effects of PTH. AREG-KO mice were characterized by unchanged distal femoral cancellous bone mass and only subtle decreases in bone mineral density (BMD) and cortical thickness at the femoral midshaft at 3 and 8 months of age, relative to wildtype controls. AREG deficiency was associated with complex changes in the mRNA expression of other EGFR ligands in femoral cancellous bone osteoblasts in situ in 3-week-old mice. To examine the bone anabolic effects of PTH in the absence and presence of AREG, we injected 3-month-old AREG-KO females and wildtype control littermates with 80 μg/kg PTH or vehicle 5 times per week over 4 weeks. Intermittent PTH treatment of AREG-KO mice led to increases in femoral trabecular and cortical BMD, cortical thickness, endocortical and periosteal bone formation, cancellous bone formation rate, and serum osteocalcin, comparable to those observed in wildtype control mice. In conclusion, our data indicate that the bone anabolic effects of PTH do not require AREG, at least in 3-month-old female mice.
Collapse
Affiliation(s)
- Freya F Jay
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany
| | - Mithila Vaidya
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, 1210 Vienna, Austria
| | - Sabrina M Porada
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany
| | - Olena Andrukhova
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, 1210 Vienna, Austria
| | - Marlon R Schneider
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, 1210 Vienna, Austria.
| |
Collapse
|
43
|
Vaidya M, Lehner D, Handschuh S, Jay FF, Erben RG, Schneider MR. Osteoblast-specific overexpression of amphiregulin leads to transient increase in femoral cancellous bone mass in mice. Bone 2015; 81:36-46. [PMID: 26103093 DOI: 10.1016/j.bone.2015.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 05/28/2015] [Accepted: 06/17/2015] [Indexed: 11/27/2022]
Abstract
The epidermal growth factor receptor ligand amphiregulin (AREG) has been implicated in bone physiology and in bone anabolism mediated by intermittent parathyroid hormone treatment. However, the functions of AREG in bone have been only incipiently evaluated in vivo. Here, we generated transgenic mice overexpressing AREG specifically in osteoblasts (Col1-Areg). pQCT analysis of the femoral metaphysis revealed increased trabecular bone mass at 4, 8, and 10weeks of age in Col1-Areg mice compared to control littermates. However, the high bone mass phenotype was transient and disappeared in older animals. Micro-CT analysis of the secondary spongiosa confirmed increased trabecular bone volume and trabecular number in the distal femur of 4-week-old AREG-tg mice compared to control littermates. Furthermore, μ-CT analysis of the primary spongiosa revealed unaltered production of new bone trabeculae in distal femora of Col1-Areg mice. Histomorphometric analysis revealed a reduced number of osteoclasts in 4-week-old Col1-Areg mice, but not at later time points. Cancellous bone formation rate remained unchanged in Col1-Areg mice at all time points. In addition, bone mass and bone turnover in lumbar vertebral bodies were similar in Col1-Areg and control mice at all ages examined. Proliferation and differentiation of osteoblasts isolated from neonatal calvariae did not differ between Col1-Areg and control mice. Taken together, these data suggest that AREG overexpression in osteoblasts induces a transient high bone mass phenotype in the trabecular compartment of the appendicular skeleton by a growth-related, non-cell autonomous mechanism, leading to a positive bone balance with unchanged bone formation and lowered bone resorption.
Collapse
Affiliation(s)
- Mithila Vaidya
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna 1210, Austria
| | - Diana Lehner
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna 1210, Austria
| | - Stephan Handschuh
- VetCore Facility for Research and Technology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna 1210, Austria
| | - Freya F Jay
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany
| | - Reinhold G Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Research, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna 1210, Austria
| | - Marlon R Schneider
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany.
| |
Collapse
|
44
|
Andrukhova O, Slavic S, Odörfer KI, Erben RG. Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J Bone Miner Res 2015; 30:1831-9. [PMID: 25858796 PMCID: PMC4973700 DOI: 10.1002/jbmr.2527] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Revised: 03/25/2015] [Accepted: 04/06/2015] [Indexed: 01/22/2023]
Abstract
Myocardial infarction (MI) is a major cause of death worldwide. Epidemiological studies have linked vitamin D deficiency to MI incidence. Because fibroblast growth factor-23 (FGF23) is a master regulator of vitamin D hormone production and has been shown to be associated with cardiac hypertrophy per se, we explored the hypothesis that FGF23 may be a previously unrecognized pathophysiological factor causally linked to progression of cardiac dysfunction post-MI. Here, we show that circulating intact Fgf23 was profoundly elevated, whereas serum vitamin D hormone levels were suppressed, after induction of experimental MI in rat and mouse models, independent of changes in serum soluble Klotho or serum parathyroid hormone. Both skeletal and cardiac expression of Fgf23 was increased after MI. Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis that may have important clinical implications and may inaugurate the new field of cardio-osteology.
Collapse
|
45
|
Wang D, Deuse T, Stubbendorff M, Chernogubova E, Erben RG, Eken SM, Jin H, Li Y, Busch A, Heeger CH, Behnisch B, Reichenspurner H, Robbins RC, Spin JM, Tsao PS, Schrepfer S, Maegdefessel L. Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis. Arterioscler Thromb Vasc Biol 2015; 35:1945-53. [PMID: 26183619 DOI: 10.1161/atvbaha.115.305597] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 07/05/2015] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Despite advances in stent technology for vascular interventions, in-stent restenosis (ISR) because of myointimal hyperplasia remains a major complication. APPROACH AND RESULTS We investigated the regulatory role of microRNAs in myointimal hyperplasia/ISR, using a humanized animal model in which balloon-injured human internal mammary arteries with or without stenting were transplanted into Rowett nude rats, followed by microRNA profiling. miR-21 was the only significantly upregulated candidate. In addition, miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen. We systemically repressed miR-21 via intravenous fluorescein-tagged-locked nucleic acid-anti-miR-21 (anti-21) in our humanized myointimal hyperplasia model. As expected, suppression of vascular miR-21 correlated dose dependently with reduced luminal obliteration. Furthermore, anti-21 did not impede reendothelialization. However, systemic anti-miR-21 had substantial off-target effects, lowering miR-21 expression in liver, heart, lung, and kidney with concomitant increase in serum creatinine levels. We therefore assessed the feasibility of local miR-21 suppression using anti-21-coated stents. Compared with bare-metal stents, anti-21-coated stents effectively reduced ISR, whereas no significant off-target effects could be observed. CONCLUSION This study demonstrates the efficacy of an anti-miR-coated stent for the reduction of ISR.
Collapse
Affiliation(s)
- Dong Wang
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Tobias Deuse
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Mandy Stubbendorff
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Ekaterina Chernogubova
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Reinhold G Erben
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Suzanne M Eken
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Hong Jin
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Yuhuang Li
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Albert Busch
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Christian-H Heeger
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Boris Behnisch
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Hermann Reichenspurner
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Robert C Robbins
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Joshua M Spin
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Philip S Tsao
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| | - Sonja Schrepfer
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.).
| | - Lars Maegdefessel
- From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.)
| |
Collapse
|
46
|
Tauer JT, Hofbauer LC, Jung R, Gerdes S, Glauche I, Erben RG, Suttorp M. Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. PLoS One 2015; 10:e0131192. [PMID: 26107505 PMCID: PMC4479438 DOI: 10.1371/journal.pone.0131192] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 05/30/2015] [Indexed: 11/19/2022] Open
Abstract
The tyrosine kinase (TK) inhibitor imatinib provides a highly effective therapy for chronic myeloid leukemia (CML) via inhibition of the oncogenic TK BCR-ABL1. However, off-target TKs like platelet-derived growth factor receptors (PDGF-R) and colony-stimulating factor-1 receptor (c-fms), involved in bone remodeling, are also inhibited. Thus, pediatric patients with CML on imatinib exhibit altered bone metabolism, leading to linear growth failure. As TKI treatment might be necessary for a lifetime, long-term effects exerted on bone in children are of major concern. Therefore, we studied the skeletal long-term effects of continuous and intermittent imatinib exposure in a juvenile rat model. Four-weeks-old male Wistar rats were chronically exposed to imatinib via drinking water over a period of 10 weeks. Animals were exposed to a standard and high imatinib dosage continuously and to the high imatinib dose intermittently. Bone mass and strength were assessed using pQCT, micro-computed tomography (μCT), and biomechanical testing at the prepubertal, pubertal, and postpubertal age. Bone length and vertebral height as well as biochemical markers of bone turnover were analyzed. Femoral and tibial bone length were dose-dependently reduced by up to 24% (p<0.0001), femoral and tibial trabecular bone mass density (BMD) were reduced by up to 25% (p<0.01), and femoral breaking strength was lowered by up to 20% (p<0.05). Intermittent exposure mitigated these skeletal effects. Long-term exposure resulted in reduced vertebral height by 15% and lower trabecular BMD by 5%. Skeletal changes were associated with suppressed serum osteocalcin (p<0.01) and non-significantly elevated serum CTX-I and PINP levels. In conclusion, imatinib mainly impaired longitudinal growth of long bones rather than the vertebrae of growing rats. Interestingly, intermittent imatinib exposure has less skeletal side effects, which may be beneficial in pediatric patients taking imatinib.
Collapse
Affiliation(s)
- Josephine T. Tauer
- Department of Pediatrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
- * E-mail:
| | - Lorenz C. Hofbauer
- Department of Internal Medicine III, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - Roland Jung
- Experimental Center of the Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - Sebastian Gerdes
- Institute for Medical Informatics and Biometry, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - Ingmar Glauche
- Institute for Medical Informatics and Biometry, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - Reinhold G. Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Meinolf Suttorp
- Department of Pediatrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
| |
Collapse
|
47
|
Erben RG. Hypothesis: Coupling between Resorption and Formation in Cancellous bone Remodeling is a Mechanically Controlled Event. Front Endocrinol (Lausanne) 2015; 6:82. [PMID: 26052311 PMCID: PMC4440405 DOI: 10.3389/fendo.2015.00082] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 05/05/2015] [Indexed: 11/13/2022] Open
Abstract
Coupling is the process that links bone resorption to formation in a temporally and spatially coordinated manner within the remodeling cycle. In order to maintain skeletal integrity, it is of crucial importance that the amount of bone resorbed matches the amount of newly formed bone in each remodeling site. Although a number of different explanatory models have been developed, the mechanisms that couple bone resorption and formation in bone remodeling are still a matter of controversy. Here, I propose a model in which coupling is achieved by biomechanical strain sensed by osteocytes within the newly built bone package. In this model, the resorption cavity created by osteoclasts results in mechanical weakening of the structural element, and, thus, in increased strain under constant loading conditions. Subsequent bone formation is initiated by strain-sensitive osteocytes in the underlying bone matrix. After osteoblastic bone formation has started, the newly built osteocyte-osteoblast network detects strain. Once the mechanical strain within the newly built bone structural unit falls below a certain threshold, bone formation stops. In this biomechanical strain-driven model, osteoblasts do not need to "know" how much bone was previously resorbed in a given site. In addition, this model does not require the transfer of any information from bone-resorbing osteoclasts to bone-forming osteoblasts, because biomechanical strain "guides" osteoblasts through their job of re-filling the resorption cavity.
Collapse
Affiliation(s)
- Reinhold G. Erben
- Institute of Physiology, Pathophysiology and Biophysics, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
48
|
Chernogubova E, Wang D, Deuse T, Stubbendorff M, Erben RG, Eken SM, Jin H, Heeger C, Behnisch B, Reichenpurner H, Robbins RC, Spin JM, Tsao PS, Schrepfer S, Maegdefessel L. Abstract 281: Local MicroRNA Modulation Using a Novel Anti-mir-21-eluting Stent Effectively Prevents In-stent Restenosis. Arterioscler Thromb Vasc Biol 2015. [DOI: 10.1161/atvb.35.suppl_1.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The major limitation of vascular angioplasty remains the occurrence of in-stent restenosis (ISR). The central role of miRNAs in the pathophysiology of the proliferative response in cardiovascular disease offers attractive concepts for possible therapeutic interventions, with systemic miRNA modulation however potentially causing substantial off-target effects. Aim of the current study was to test the feasibility of local miRNA modulation using drug eluted stent (DES) technology.
Utilizing human ISR tissue samples, as well as a humanized rodent model of balloon-injured human internal mammary arteries with subsequent stent implantation in RNU rats, we were able to identify several miRNAs dys-regulated, including the well-characterized miR-21. We inhibited miR-21 (with a FAM-tagged-LNA-anti-miR-21), using either systemic or local delivery via DES.
Systemic suppression of miR-21 showed a dose-dependent reduction of luminal obliteration, while not impeding vascular re-endothelialization. However, miR-21 expression in liver, heart, lung, and kidney appeared significantly reduced, with increased levels of serum creatinine, pointing towards the expected off-target effects of systemic miRNA modulation. Local mir-21 suppression, using the anti-miR-21-DES, effectively reduced myointimal hyperplasia and ISR compared to bare metal stents, while not exerting detectable off-target effects on any other organ we investigated. Additional in vitro experiments in cultured human coronary artery smooth muscle and endothelial cells further confirmed the ability of anti_miR-21 to limit SMC proliferation and migration by repressing mRNA and protein levels of its established target PTEN, while not affecting the proliferative response in the ECs.
This is the first experimental study to demonstrate the efficacy, feasibility and suitability of an anti-miRNA-eluting stent (anti-miR-21-DES) for the reduction of ISR through dominant inhibition of SMC proliferation.
Collapse
Affiliation(s)
| | - Dong Wang
- Regenerative cell therapy, Cardiovascular Rsch Cntr, Hamburg, Germany
| | - Tobias Deuse
- Cardiovascular Surgery, Univ Heart Cntr, Hamburg, Germany
| | | | - Reinhold G Erben
- Unit of Physiology, Pathophysiology, and Experimental Endocrinology, Univ of Veterinary Medicine, Vienna, Austria
| | | | - Hong Jin
- of Medicine, Karolinska Institute, Stockholm, Sweden
| | | | | | | | - Robert C Robbins
- Dept of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford Univ, Stanford, CA
| | - Joshua M Spin
- Stanford Cardiovascular Institute, Stanford Univ, Stanford, CA
| | - Philip S Tsao
- Stanford Cardiovascular Institute, Stanford Univ, Stanford, CA
| | | | | |
Collapse
|
49
|
Sun N, Guo Y, Liu W, Densmore M, Shalhoub V, Erben RG, Ye L, Lanske B, Yuan Q. FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. Sci Rep 2015; 5:8304. [PMID: 25665715 PMCID: PMC4322353 DOI: 10.1038/srep08304] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Accepted: 12/16/2014] [Indexed: 02/05/2023] Open
Abstract
Chronic kidney disease (CKD) is a worldwide health problem. Serum levels of FGF23, a phosphaturic hormone, increase at the earliest stages of CKD, and have been found to be independently associated with the mortality and morbidity of CKD patients. The purpose of this study was to evaluate whether FGF23 neutralization was able to improve bone quality and osseointegration of titanium implants. Uremia was induced by 5/6 nephrectomy in adult female mice. Postsurgery, the mice were injected with vehicle or FGF23 neutralizing antibody (5 mg/kg body weight) 3 times a week. Experimental titanium implants were inserted in the distal end of the femurs. FGF23 neutralization significantly increased serum phosphate, 1,25(OH)2D and BUN, and decreased serum PTH and FGF23, relative to vehicle-treated CKD mice. Histomorphometric analysis of the tibiae indicated that FGF23 neutralization normalized the osteoidosis observed in vehicle-treated CKD mice. Although bone-implant contact ratio remained unchanged by anti-FGF23 antibody treatment, the strength of osseointegration, as evidenced by a biomechanical push-in test, was significantly improved by FGF23 neutralization. Our findings revealed that FGF23 neutralization effectively improves bone quality and osseointegration of titanium implants in CKD mice, suggesting FGF23 as a key factor of CKD related bone diseases.
Collapse
Affiliation(s)
- Ningyuan Sun
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Yuchen Guo
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Weiqing Liu
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Michael Densmore
- Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA
| | | | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
| | - Ling Ye
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Beate Lanske
- Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA
| | - Quan Yuan
- 1] State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China [2] Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA
| |
Collapse
|
50
|
Zwolanek D, Flicker M, Kirstätter E, Zaucke F, van Osch GJVM, Erben RG. β1 Integrins Mediate Attachment of Mesenchymal Stem Cells to Cartilage Lesions. Biores Open Access 2015; 4:39-53. [PMID: 26309781 PMCID: PMC4497673 DOI: 10.1089/biores.2014.0055] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Mesenchymal stem cells (MSC) may have great potential for cell-based therapies of osteoarthritis. However, after injection in the joint, only few cells adhere to defective articular cartilage and contribute to cartilage regeneration. Little is known about the molecular mechanisms of MSC attachment to defective articular cartilage. Here, we developed an ex vivo attachment system, using rat osteochondral explants with artificially created full-thickness cartilage defects in combination with genetically labeled MSC isolated from bone marrow of human placental alkaline phosphatase transgenic rats. Binding of MSC to full-thickness cartilage lesions was improved by serum, but not hyaluronic acid, and was dependent on the presence of divalent cations. Additional in vitro tests showed that rat MSC attach, in a divalent cation-dependent manner, to collagen I, collagen II, and fibronectin, but not to collagen XXII or cartilage oligomeric matrix protein (COMP). RGD peptides partially blocked the adhesion of MSC to fibronectin in vitro and to cartilage lesions ex vivo. Furthermore, the attachment of MSC to collagen I and II in vitro and to cartilage lesions ex vivo was almost completely abolished in the presence of a β1 integrin blocking antibody. In conclusion, our data suggest that attachment of MSC to ex vivo full-thickness cartilage lesions is almost entirely β1 integrin-mediated, whereby both RGD- and collagen-binding integrins are involved. These findings suggest a key role of integrins during MSC attachment to defective cartilage and may pave the way for improved MSC-based therapies in the future.
Collapse
Affiliation(s)
- Daniela Zwolanek
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Magdalena Flicker
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Elisabeth Kirstätter
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Frank Zaucke
- Center for Biochemistry and Cologne Center for Musculoskeletal Biomechanics, Medical Faculty, University of Cologne , Cologne, Germany
| | - Gerjo J V M van Osch
- Department of Orthopaedics and Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam , Rotterdam, The Netherlands
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| |
Collapse
|